US.ABBV · AbbVie

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.687624484186888,
        "turnoverUsdM": 870.23582635563,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.ABBV",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 237.3378,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 1,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 5.4,
      "take_profit_price": 263.361,
      "target_multiplier": 1.6,
      "technical_strength": 1.38,
      "take_profit_percent": 5
    },
    "positionPoints": 1.6,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 5.375248968373776,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 54.4,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 49.4,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 5
  },
  "market": {
    "ma20": 252.398,
    "ma50": 243.8126,
    "close": 250.82,
    "prevClose": 248.76,
    "avgVolume20": 5379273,
    "volumeRatio": 0.64,
    "changePercent": 0.83
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 5,
    "details": {
      "ret_5d": 0.028498831344568876,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 5,
      "vcp_bonus": 0,
      "vol_ratio": 0.6270026402485195,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 1.0125045930515133,
      "volat_points": 0,
      "day_range_pct": 0.023702215784139353,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 54.4,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.3,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 46,
        "contribution": 2.3
      },
      {
        "raw": 8.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 42,
        "contribution": 8.4
      },
      {
        "raw": 8,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 53.33,
        "contribution": 8
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.8,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 68,
        "contribution": 6.8
      },
      {
        "raw": 15.9,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 53,
        "contribution": 15.9
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 49.4,
    "details": [
      "基本面分析總分: 2.3/5分",
      "資金流分析總分: 8.4/20分",
      "市場環境分析總分: 8/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.8/10分",
      "技術信號分析總分: 15.9/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.3,
      "資金流": 8.4,
      "市場環境": 8,
      "情緒分析": 6,
      "技術信號": 15.9,
      "風險管理": 6.8
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.3,
          "marginPoints": 0,
          "turnoverUsdM": 870.23582635563,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 0.8,
          "obvPoints": 4,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.ABBV",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 3.4,
            "details": {
              "qqq": {
                "ma20": 702.3384985500002,
                "ma50": 713.21300206,
                "name": "QQQ",
                "close": 732.070007,
                "points": 1.4
              },
              "spy": {
                "ma20": 754.5440030999999,
                "ma50": 748.4844041399998,
                "name": "SPY",
                "close": 777.88,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.687624484186888,
          "atrPoints": 3,
          "cciPoints": 1.6,
          "vixPoints": 0,
          "marketTrendPoints": 3.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 4,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141210872,
                "url": "https://finnhub.io/api/news?id=0dbf6b24d123f0a154351a53eec26a89c1aa6fe99f4dd3171433292f42b33bbf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally). The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which exceeded internal expectations despite including a $0.41 per share unfavorable impact from acquired IPR&D […]",
                "category": "company",
                "datetime": 1786656786,
                "headline": "Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?"
              },
              {
                "id": 141207923,
                "url": "https://finnhub.io/api/news?id=88a90702b18759d550549111dea289f1d88362148d397438d1ad60ef07c20c75",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.",
                "category": "company",
                "datetime": 1786637411,
                "headline": "The Sharpest Exchanges From ABBV's Earnings Call"
              },
              {
                "id": 141200401,
                "url": "https://finnhub.io/api/news?id=9f8326d5bf4c5cc8712afd3a3a64b28f795699272f51d641a706f97680ee3451",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The drugmaker's operating numbers are near the top of its class, but its stock performance is lagging the pack. Is the market seeing a risk that the fundamentals are missing.",
                "category": "company",
                "datetime": 1786567769,
                "headline": "How ABBV Stock Moved Away From Its Peer Group"
              },
              {
                "id": 141200618,
                "url": "https://finnhub.io/api/news?id=13f1298ebc4c518c0dd79feda3636de8fb9afa9966b4932b224c23998ef49532",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) received a recommendation from Canada's Drug Agency to reimburse UBRELVY for the acute treatment of migraine in adults. The decision follows Phase 3 trial results and a review process that included direct input from patients and clinicians. The recommendation expands access to UBRELVY in Canada and broadens AbbVie's neuroscience portfolio in migraine care. For more ideas in this area, take a look at 43 healthcare AI stocks. NYSE:ABBV Earnings & Revenue Growth as at Aug...",
                "category": "company",
                "datetime": 1786486514,
                "headline": "AbbVie (ABBV) Wins Canada Reimbursement Backing For Adult Migraine Treatment"
              },
              {
                "id": 141200620,
                "url": "https://finnhub.io/api/news?id=51347be87f89806a9331772ef84322ca498b19554d6d04c6e9f0864dd5d05b81",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) is back in focus after Allergan Aesthetics reported that the FDA accepted a supplemental Biologics License Application for Botox Cosmetic targeting masseter muscle prominence in adults, which would be a potential fifth U.S. aesthetic indication. See our latest analysis for AbbVie. Alongside Allergan Aesthetics' Botox update and several recent approvals and guidance changes, AbbVie’s share price has moved to $247.97, with a 90 day share price return of 19.3% and a 1 year total...",
                "category": "company",
                "datetime": 1786482692,
                "headline": "AbbVie (ABBV) Gains On Botox Filing, Is The 9% Discount Still There?"
              },
              {
                "id": 141176631,
                "url": "https://finnhub.io/api/news?id=ca413707af7b6ebc1e4b5a8d925fc732324d990c17033e1fcd8bfdcb0a5c22ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) just moved a step closer to expanding one of its most recognizable brands. On August 4, the FDA accepted for review a supplemental Biologics License Application for Botox Cosmetic to treat masseter muscle prominence, the jaw-muscle bulge that can give a face a wider, squarer look. If cleared, Botox Cosmetic would become the […]",
                "category": "company",
                "datetime": 1786381180,
                "headline": "AbbVie’s (ABBV) Botox Just Got A Step Closer To A Fifth Use"
              },
              {
                "id": 141152475,
                "url": "https://finnhub.io/api/news?id=b90d636c4769ab650549fd4b8dc6d371e94f4881e136739b0611111754981b16",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "In late July and early August 2026, AbbVie reported stronger second‑quarter results, raised full‑year revenue guidance to about US$67.6 billion, advanced RINVOQ and BOTOX regulatory milestones, and completed a multi‑billion‑dollar mix of new fixed‑ and floating‑rate bond issuances. Together, these moves highlight how AbbVie is simultaneously expanding its immunology, neuroscience and aesthetics franchises while tapping debt markets to support its pipeline and deals such as the planned Apogee...",
                "category": "company",
                "datetime": 1786133683,
                "headline": "AbbVie (ABBV) Is Down 5.3% After Raising 2026 Revenue Outlook and Issuing New Debt - What's Changed"
              },
              {
                "id": 141137156,
                "url": "https://finnhub.io/api/news?id=2f69e9460fe0aae9ead0dc803c5110b49010b128ce55b4a38234a0a34db793d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "ABBV falls after cutting its 2026 EPS outlook to reflect the Apogee deal, despite strong Q2 results, higher revenue guidance and growth from key medicines.",
                "category": "company",
                "datetime": 1786031340,
                "headline": "ABBV Stock Dips 4% Despite Robust Q2: Buy the Dip or Stay Cautious?"
              }
            ],
            "raw_source": [
              {
                "id": 141210872,
                "url": "https://finnhub.io/api/news?id=0dbf6b24d123f0a154351a53eec26a89c1aa6fe99f4dd3171433292f42b33bbf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally). The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which exceeded internal expectations despite including a $0.41 per share unfavorable impact from acquired IPR&D […]",
                "category": "company",
                "datetime": 1786656786,
                "headline": "Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?"
              },
              {
                "id": 141207923,
                "url": "https://finnhub.io/api/news?id=88a90702b18759d550549111dea289f1d88362148d397438d1ad60ef07c20c75",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.",
                "category": "company",
                "datetime": 1786637411,
                "headline": "The Sharpest Exchanges From ABBV's Earnings Call"
              },
              {
                "id": 141206518,
                "url": "https://finnhub.io/api/news?id=9069d19d991acf04b9fca1c8a243ae50a474fe8d50a62762c1f60f1f800987d3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts.",
                "category": "company",
                "datetime": 1786629121,
                "headline": "Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation"
              },
              {
                "id": 141209899,
                "url": "https://finnhub.io/api/news?id=d1a76c860af5738244eaf199d5b7aadc2e317507eca44c358c8ce07d3a785a86",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Wolfe Research  analyst Alexandria Hammond   upgrades AbbVie (NYSE:ABBV) from Peer Perform to Outperform and announces $300 price target.",
                "category": "company",
                "datetime": 1786626886,
                "headline": "Wolfe Research Upgrades AbbVie to Outperform, Announces $300 Price Target"
              },
              {
                "id": 141204884,
                "url": "https://finnhub.io/api/news?id=2f7edaf5d4d41b70d1c840109cb90b6618fd34f237bd841243f92642f438c4d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Wall Street analysts made bold moves Thursday, slashing targets on some names while dramatically upgrading others, and the gap between winners and losers tells a story about where smart money is quietly repositioning ahead of the next market move.",
                "category": "company",
                "datetime": 1786622027,
                "headline": "Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More"
              },
              {
                "id": 141203838,
                "url": "https://finnhub.io/api/news?id=b33f48fc75f1b9ffcfdf982f5269f978b42b2ad1137e5f452919966d0bda6944",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2249791973/image_2249791973.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Key Contributors include Palo Alto Networks, ASML Holding, and Taiwan Semiconductor. Read more here.",
                "category": "company",
                "datetime": 1786596000,
                "headline": "American Century Focused Global Growth Fund Q2 2026 Portfolio Review"
              },
              {
                "id": 141200401,
                "url": "https://finnhub.io/api/news?id=9f8326d5bf4c5cc8712afd3a3a64b28f795699272f51d641a706f97680ee3451",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The drugmaker's operating numbers are near the top of its class, but its stock performance is lagging the pack. Is the market seeing a risk that the fundamentals are missing.",
                "category": "company",
                "datetime": 1786567769,
                "headline": "How ABBV Stock Moved Away From Its Peer Group"
              },
              {
                "id": 141200512,
                "url": "https://finnhub.io/api/news?id=00bc77a193caee8506d9c2f7e49efdf6fa5f4b117ad9f052361cece75a324ba4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Management raised its full-year forecast, but the market seems to be asking for more than a higher target.",
                "category": "company",
                "datetime": 1786562251,
                "headline": "Amgen Stock And The Price Of A Promise"
              },
              {
                "id": 141200513,
                "url": "https://finnhub.io/api/news?id=c73a8f0475758d31cd448380b74cbbb1c57e712f593a1a9679b90a05f53a54ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Two healthcare giants, two very different dividend bets: one built on six decades of unbroken raises and a fortress balance sheet, the other dangling a fatter yield while racing to outrun its own blockbuster's collapse. Knowing which risk you are actually buying changes everything.",
                "category": "company",
                "datetime": 1786559422,
                "headline": "Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield"
              },
              {
                "id": 141200500,
                "url": "https://finnhub.io/api/news?id=ff75988727fcba1e5d818840746487c01f069e154db33e9b2aabc87f756101ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Four dividend giants from energy and pharma quietly generate the bulk of HDV's income, but their balance sheets and payout coverage look nothing alike. Before trusting that 3% yield, it pays to know which checks are ironclad and which carry a hidden catch.",
                "category": "company",
                "datetime": 1786551148,
                "headline": "The Energy and Pharma Giants Quietly Funding HDV’s 3% Yield, and How Safe Each One Is"
              },
              {
                "id": 141189365,
                "url": "https://finnhub.io/api/news?id=3af242c14af2e122129a8e9419b3189b5d2cbedcadc8635aa37d3a59154b3ac7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "This healthcare giant is on a serious run, but with the stock trading at a peak, investors must decide if the powerful business engine has more fuel or if the price has already burned it all.",
                "category": "company",
                "datetime": 1786489797,
                "headline": "JNJ Keeps Climbing. Should You Climb On?"
              },
              {
                "id": 141200618,
                "url": "https://finnhub.io/api/news?id=13f1298ebc4c518c0dd79feda3636de8fb9afa9966b4932b224c23998ef49532",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) received a recommendation from Canada's Drug Agency to reimburse UBRELVY for the acute treatment of migraine in adults. The decision follows Phase 3 trial results and a review process that included direct input from patients and clinicians. The recommendation expands access to UBRELVY in Canada and broadens AbbVie's neuroscience portfolio in migraine care. For more ideas in this area, take a look at 43 healthcare AI stocks. NYSE:ABBV Earnings & Revenue Growth as at Aug...",
                "category": "company",
                "datetime": 1786486514,
                "headline": "AbbVie (ABBV) Wins Canada Reimbursement Backing For Adult Migraine Treatment"
              },
              {
                "id": 141189366,
                "url": "https://finnhub.io/api/news?id=875b935af433bfa3030edf6eff7cc254c4ffb82289f22197cb75fd2f1a2404bd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Pfizer sent shareholders a fortune in cash, yet the stock fell far behind the market, forcing a hard question about what all that money truly bought.",
                "category": "company",
                "datetime": 1786484330,
                "headline": "$49 Billion In Payouts, A Lagging Stock: The PFE Trade-Off"
              },
              {
                "id": 141200620,
                "url": "https://finnhub.io/api/news?id=51347be87f89806a9331772ef84322ca498b19554d6d04c6e9f0864dd5d05b81",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) is back in focus after Allergan Aesthetics reported that the FDA accepted a supplemental Biologics License Application for Botox Cosmetic targeting masseter muscle prominence in adults, which would be a potential fifth U.S. aesthetic indication. See our latest analysis for AbbVie. Alongside Allergan Aesthetics' Botox update and several recent approvals and guidance changes, AbbVie’s share price has moved to $247.97, with a 90 day share price return of 19.3% and a 1 year total...",
                "category": "company",
                "datetime": 1786482692,
                "headline": "AbbVie (ABBV) Gains On Botox Filing, Is The 9% Discount Still There?"
              },
              {
                "id": 141200621,
                "url": "https://finnhub.io/api/news?id=a08e7c7fa18be82606ea2feeb7ddeeada1626fe5e95e301c926252196ccedab8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie commands a premium valuation for its specialty drug pipeline, while CVS Health trades at a discount despite managing 37 million medical members.",
                "category": "company",
                "datetime": 1786481221,
                "headline": "AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 141189360,
                "url": "https://finnhub.io/api/news?id=f5932c9df04bd778e326a6ee5cebd833aba4d5b273c91902ce74816c1abdff6e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Both of these stocks pay more than double the S&P 500 average of 1.1%.",
                "category": "company",
                "datetime": 1786468523,
                "headline": "Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026?"
              },
              {
                "id": 141200526,
                "url": "https://finnhub.io/api/news?id=bb45ea9039c763833121ecfb68e434d16b3cf6fb8431480eca4c3f9568d605b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Skyrizi and Rinvoq drive ABBV's Q2 growth, with strong sales, market-share gains and new indications supporting the immunology franchise.",
                "category": "company",
                "datetime": 1786467240,
                "headline": "How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?"
              },
              {
                "id": 141200624,
                "url": "https://finnhub.io/api/news?id=36b93b198d828126826d33226504fa9d1104c2738ade7d2bb2d617000b8f436b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Eli Lilly just posted its fourth straight earnings beat and raised guidance again, but the real question is whether a next-generation obesity drug still sitting below Wall Street's radar could push the stock well past current targets.",
                "category": "company",
                "datetime": 1786460414,
                "headline": "Eli Lilly Beat Big and Raised Guidance. Wall Street Sees More Room to Run"
              },
              {
                "id": 141188929,
                "url": "https://finnhub.io/api/news?id=054e1ed058edf4927c19ffb2c9283479609da027175841f5bcaabb478837c7e6",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "BNP Paribas  analyst Navann Ty   maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $218 to $247.",
                "category": "company",
                "datetime": 1786456534,
                "headline": "BNP Paribas Maintains Neutral on AbbVie, Raises Price Target to $247"
              },
              {
                "id": 141200625,
                "url": "https://finnhub.io/api/news?id=a4f64e1367b0eeac052bdbb21dc48e23a1ab4e3feac3e16bc11a981beb1d3c2d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Allergan Aesthetics, an AbbVie company, today announced updates to Allergan Partner Privileges® (APP), its customer portfolio loyalty program, designed to better support the way today's aesthetics practices operate and grow. Shaped by customer feedback and market momentum, the program now introduces simpler savings, greater benefits transparency and expanded opportunities for practice growth, making it easier for customers to understand, access and maximize the value of their partnership with Al",
                "category": "company",
                "datetime": 1786449600,
                "headline": "Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices"
              },
              {
                "id": 141200626,
                "url": "https://finnhub.io/api/news?id=49ac0507a45d1cb7207a32be4124e84155f52820dbe80fd6ed5d4efd0ede2563",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The pharmaceutical company hopes that another big-time acquisition will pay off.",
                "category": "company",
                "datetime": 1786446300,
                "headline": "AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?"
              },
              {
                "id": 141180189,
                "url": "https://finnhub.io/api/news?id=328cfb139ab5465f3851efd62dfbb11509b58513062093c5cf9c4e71670002a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Eli Lilly's growth is huge, but on its latest call, analysts tested whether the next chapter can possibly live up to the last one.",
                "category": "company",
                "datetime": 1786402912,
                "headline": "What Analysts Really Pressed LLY On This Quarter"
              },
              {
                "id": 141176631,
                "url": "https://finnhub.io/api/news?id=ca413707af7b6ebc1e4b5a8d925fc732324d990c17033e1fcd8bfdcb0a5c22ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) just moved a step closer to expanding one of its most recognizable brands. On August 4, the FDA accepted for review a supplemental Biologics License Application for Botox Cosmetic to treat masseter muscle prominence, the jaw-muscle bulge that can give a face a wider, squarer look. If cleared, Botox Cosmetic would become the […]",
                "category": "company",
                "datetime": 1786381180,
                "headline": "AbbVie’s (ABBV) Botox Just Got A Step Closer To A Fifth Use"
              },
              {
                "id": 141176602,
                "url": "https://finnhub.io/api/news?id=9619ef377aa37b3295cafc7d2a4686061b76f5c87f4c8df7da46959859930693",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The case for more upside rests on its obesity pill, and what changed is not the drug but who can now write it and who can now pay for it.",
                "category": "company",
                "datetime": 1786377692,
                "headline": "Eli Lilly Stock's Next Climb Runs Through A Pill, Not Just An Injection"
              },
              {
                "id": 141175296,
                "url": "https://finnhub.io/api/news?id=f343afcf599cec5059f6e3384f6e1fcfe83b4c90004ff60e199ddf20e99103ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The stock is up just 8% this year and could prove to be an undervalued buy.",
                "category": "company",
                "datetime": 1786370641,
                "headline": "Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?"
              },
              {
                "id": 141174297,
                "url": "https://finnhub.io/api/news?id=69abc7bda0fef2cc41514d6b8a86bc01b40e4cb7b2b108f5ac878016d42a3aad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Four Dividend Aristocrats were flagged as stealth growth plays a year ago, and the results cut sharply in two directions. See which names delivered and which stumbled, plus three fresh picks where the dividend coverage story is quietly getting stronger.",
                "category": "company",
                "datetime": 1786369539,
                "headline": "We Said These 4 Dividend Aristocrats Could Soar. Here’s How They Did, Plus 3 New Picks."
              },
              {
                "id": 141176420,
                "url": "https://finnhub.io/api/news?id=c051b59f5a73b56e38d6aba01c778ec561b3bfd020bd5ce34cb5a2533cb10b81",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Evercore ISI Group  analyst Gavin Clark-Gartner   maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $246 to $260.",
                "category": "company",
                "datetime": 1786363337,
                "headline": "Evercore ISI Group Maintains Outperform on AbbVie, Raises Price Target to $260"
              },
              {
                "id": 141173839,
                "url": "https://finnhub.io/api/news?id=cdede5a86a1a9c715bcc2916ec012ef4f51f2e1958b7fa818b04daf0ff357e39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Healthcare just posted the best three-month run of any S&P 500 sector, yet two of the three biggest pharma names by market cap are still trailing the broader market. That gap between performance and fundamentals is creating a window that income and growth investors rarely see at the mega-cap level.",
                "category": "company",
                "datetime": 1786363255,
                "headline": "3 Beaten-Down Healthcare Stocks to Buy in August"
              },
              {
                "id": 141174738,
                "url": "https://finnhub.io/api/news?id=79f38d590e34e831d31db42477bd1fdbd5b0b46115fb301503409749e238a15b",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Apogee Therapeutics (NASDAQ:APGE) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(1.05) by 8.57 percent. This is a 0.88 percent decrease over losses of $(1.13) per share",
                "category": "company",
                "datetime": 1786346565,
                "headline": "Apogee Therapeutics Q2 EPS $(1.14) Misses $(1.05) Estimate"
              },
              {
                "id": 141170024,
                "url": "https://finnhub.io/api/news?id=d0da7ae1c82aa7f3246b7500985fb1b061b1cb20ab34f3c7b72861cac2bd7407",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie’s second quarter results reflected robust product performance but were met with cautious investor sentiment. Management credited double-digit sales growth to strong execution in core immunology therapies, especially SKYRIZI and RINVOQ, and notable gains in the neuroscience portfolio. CEO Robert Michael emphasized that “each [portfolio] delivered growth above 20%,” with SKYRIZI achieving market leadership in multiple countries. However, the quarter also saw persistent biosimilar pressure o",
                "category": "company",
                "datetime": 1786318402,
                "headline": "The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call"
              },
              {
                "id": 141152474,
                "url": "https://finnhub.io/api/news?id=3852ba4223d6f6fd4381be34a82f8c1b6dd45b23181cf2e6ab311afb3d93f615",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie generates stronger free cash flow and trades at a lower forward multiple, while Abbott offers diversification and a healthier balance sheet.",
                "category": "company",
                "datetime": 1786135497,
                "headline": "AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 141152475,
                "url": "https://finnhub.io/api/news?id=b90d636c4769ab650549fd4b8dc6d371e94f4881e136739b0611111754981b16",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "In late July and early August 2026, AbbVie reported stronger second‑quarter results, raised full‑year revenue guidance to about US$67.6 billion, advanced RINVOQ and BOTOX regulatory milestones, and completed a multi‑billion‑dollar mix of new fixed‑ and floating‑rate bond issuances. Together, these moves highlight how AbbVie is simultaneously expanding its immunology, neuroscience and aesthetics franchises while tapping debt markets to support its pipeline and deals such as the planned Apogee...",
                "category": "company",
                "datetime": 1786133683,
                "headline": "AbbVie (ABBV) Is Down 5.3% After Raising 2026 Revenue Outlook and Issuing New Debt - What's Changed"
              },
              {
                "id": 141150983,
                "url": "https://finnhub.io/api/news?id=dd12bcdfe4ed22cf3954c88504072df39a69214fa699b7fae9f00c2150af3b44",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "If you hold shares, you're already exposed to a potential future where the stock is either far higher or far lower, and the options market is pricing both as real possibilities.",
                "category": "company",
                "datetime": 1786127896,
                "headline": "The Two Divergent Paths Priced Into Eli Lilly Stock"
              },
              {
                "id": 141152423,
                "url": "https://finnhub.io/api/news?id=af72a397d825898b459a1a054ad11e152f22a3d67f610472c2aab599efe41d41",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Weekly dividend activity roundup for Dividend Champions, Contenders & Challengers—see dividend changes, upcoming ex-dividend dates and pay dates here.",
                "category": "company",
                "datetime": 1786125278,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of August 9"
              },
              {
                "id": 141151021,
                "url": "https://finnhub.io/api/news?id=db89ffb6a4e42d5346028ad604677dfe666fde3976466e11bfea0e10028f27bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "IRWD tops Q2 earnings estimates, misses on revenues and lifts its 2026 outlook as strong Linzess demand drives year-over-year growth.",
                "category": "company",
                "datetime": 1786121580,
                "headline": "Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised"
              },
              {
                "id": 141144662,
                "url": "https://finnhub.io/api/news?id=c788d44770abb69329f91e62fdaa825f7bcc95adbe6ddc7ed9740f7b0bb37c05",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.",
                "category": "company",
                "datetime": 1786116600,
                "headline": "These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks"
              },
              {
                "id": 141146290,
                "url": "https://finnhub.io/api/news?id=073123c4b31e553d2572c2822ba658bac9a5787f0a57ddd4413bf144a3348847",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "REGENXBIO (NASDAQ:RGNX) reported second-quarter 2026 progress across its late-stage gene-therapy pipeline, highlighting completed enrollment in its Duchenne muscular dystrophy confirmatory study, an agreed path to resubmit its Hunter syndrome therapy application, and the start of a pivotal diabetic",
                "category": "company",
                "datetime": 1786100635,
                "headline": "REGENXBIO Q2 Earnings Call Highlights"
              },
              {
                "id": 141140401,
                "url": "https://finnhub.io/api/news?id=e101b5936974d060a563dddc97f11a0b8de11bef1f7aa6e60687465b8d41392e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Regenxbio advances RGX-202 and RGX-121 programs while securing $208 million in new funding to support operations through late 2027.",
                "category": "company",
                "datetime": 1786042973,
                "headline": "Regenxbio Inc (RGNX) (Q2 2026) Earnings Call Highlights: Cash Runway Extended into Q4 2027 on ..."
              },
              {
                "id": 141137106,
                "url": "https://finnhub.io/api/news?id=13924ec932305c2a9448f9e2ae9ac52f8af0e2e6a13c7132c5bb76ff66330f7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "JEPI's fat monthly yield has made it a retiree favorite, but a smaller rival running a completely different options playbook has quietly compounded far more wealth over the same period without sacrificing the monthly income routine investors depend on.",
                "category": "company",
                "datetime": 1786032359,
                "headline": "The 6.4% Monthly Payer That Beat JEPI by 8 Points With No NAV Bleed"
              },
              {
                "id": 141137156,
                "url": "https://finnhub.io/api/news?id=2f69e9460fe0aae9ead0dc803c5110b49010b128ce55b4a38234a0a34db793d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "ABBV falls after cutting its 2026 EPS outlook to reflect the Apogee deal, despite strong Q2 results, higher revenue guidance and growth from key medicines.",
                "category": "company",
                "datetime": 1786031340,
                "headline": "ABBV Stock Dips 4% Despite Robust Q2: Buy the Dip or Stay Cautious?"
              },
              {
                "id": 141133236,
                "url": "https://finnhub.io/api/news?id=d05725a4e5530ffbaa9a602865085d7eca56d38ae76b509ab7846a4a82faa6a9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and operational highlights for the second quarter ended June 30, 2026.",
                "category": "company",
                "datetime": 1786014300,
                "headline": "REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights"
              },
              {
                "id": 141133788,
                "url": "https://finnhub.io/api/news?id=ccfe548320a03015e958d00e621de8931f2aaa56083a349960ae1c56ad152b8d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359351391/image_1359351391.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Discover Seeking Alpha’s July spotlight on top new analysts and highest‑conviction stock ideas—from Strong Sell to Strong Buy.",
                "category": "company",
                "datetime": 1786006800,
                "headline": "Stock Picks From Seeking Alpha's July 2026 New Analysts"
              },
              {
                "id": 141135283,
                "url": "https://finnhub.io/api/news?id=61b54d952a72f4dae3b74529ad2a238f7f8fa29b096a0fde8d3c13db7000a809",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/06/Valhalla--Ny--Usa---May-10--2023-Governo.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Kathy Hochul says Trump's Medicare subsidy decision will raise prescription drug costs for 1.3 million New Yorkers.",
                "category": "company",
                "datetime": 1785987665,
                "headline": "Kathy Hochul Slams Trump Over Medicare Cut, Says 1.3 Million New Yorkers Will Pay More for Prescriptions: 'A New Assault on Seniors...'"
              },
              {
                "id": 141130013,
                "url": "https://finnhub.io/api/news?id=7483d7b586d5468d6252462a946d27bac340979c4a16c1f9509dc07c879b992b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "There is no end in sight for the drugmaker's dividend growth streak.",
                "category": "company",
                "datetime": 1785979200,
                "headline": "This Stock Keeps Raising Its Dividend No Matter What the Market Does -- and Wall Street Thinks It's a Buy Right Now"
              },
              {
                "id": 141127414,
                "url": "https://finnhub.io/api/news?id=70b784d51037fc27f530c0693cd7ca54aaa42aced8229c9033418c5edab4fcf2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The market is pricing in an unusually high cash-generation yield for one of the world's largest drugmakers, forcing investors to decide if the price reflects a temporary problem or a permanent decline.",
                "category": "company",
                "datetime": 1785964991,
                "headline": "Why PFE Stock Hands You So Much Cash Right Now"
              },
              {
                "id": 141126014,
                "url": "https://finnhub.io/api/news?id=4ca154ba64515bee5ba02348b2bcfc96c4b3f716d2aaef53bf1dd2abbbbb6145",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2217256698/image_2217256698.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Teva Pharmaceutical Industries Limited turnaround: Pivot to Growth, raised 2026 guidance, $3.7B specialty target, and more. Click for this TEVA update.",
                "category": "company",
                "datetime": 1785945929,
                "headline": "Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan"
              },
              {
                "id": 141122396,
                "url": "https://finnhub.io/api/news?id=e27cb2755c5c26998a75d4cb2de83f1f6b0204bab0546d82cb0ec6f2e4beebbb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie's blockbuster drugs are surging while a major acquisition looms, but a trailing P/E of 71 and one model pricing the stock nearly $50 below current levels raises a real question about whether the rally has room left to run.",
                "category": "company",
                "datetime": 1785938426,
                "headline": "Prediction: AbbVie Will End The Year at This Price"
              },
              {
                "id": 141122397,
                "url": "https://finnhub.io/api/news?id=a5d12c161719fec86d0953667d5106489f878b197dcd136d8bded74bb49fddca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "According to the average brokerage recommendation (ABR), one should invest in AbbVie (ABBV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
                "category": "company",
                "datetime": 1785936603,
                "headline": "Is It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views?"
              },
              {
                "id": 141121210,
                "url": "https://finnhub.io/api/news?id=ded11a9aaaddbe35c2d7f52a8a4439ad63809fe94831a4593b0689c261baaa92",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]",
                "category": "company",
                "datetime": 1785932245,
                "headline": "Baron Capital Exits Apogee Therapeutics (APGE) Following AbbVie Buyout"
              },
              {
                "id": 141121211,
                "url": "https://finnhub.io/api/news?id=06a6c05372c8650453ae2310000521ca952894db264efd78001e09f650b3a829",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Zifo's 2026 Scientific Informatics Experience Exchange (SiEE) in Basel convened leading experts from companies such as Roche, Bayer, Novo Nordisk, Galapagos, AbbVie, and Syngenta to tackle the industry's most pressing challenge: ensuring current digital and AI executions rest on solid data foundations while preparing for the next frontier of technological disruption.",
                "category": "company",
                "datetime": 1785931200,
                "headline": "A New Biopharma Roadmap: Zifo's SiEE Basel Event Puts Data Before AI Hype"
              },
              {
                "id": 141116446,
                "url": "https://finnhub.io/api/news?id=4294721d5e797a3d92009c32ef6716dc6e1e8a0b9dc7fd9a3a6b723551b37502",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Allergan Aesthetics, an AbbVie company, reported that the FDA has accepted for review a supplemental Biologics License Application for BOTOX Cosmetic to treat masseter muscle prominence. If cleared, BOTOX Cosmetic would be the first neurotoxin approved in the U.S. for this condition, supported by positive Phase 3 trial data. The filing highlights AbbVie’s push to broaden its aesthetics offerings beyond current BOTOX Cosmetic indications. AbbVie (NYSE:ABBV) is drawing fresh attention to its...",
                "category": "company",
                "datetime": 1785881502,
                "headline": "AbbVie (ABBV) Wins FDA Review For BOTOX Cosmetic In Jawline Treatment Push"
              },
              {
                "id": 141113199,
                "url": "https://finnhub.io/api/news?id=0f21837584c1a925e9fe4fed0c754b296971f9a558761b1fc426bddbd7a6ffd8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index down 0.7% and th",
                "category": "company",
                "datetime": 1785872648,
                "headline": "Sector Update: Healthcare Stocks Softer Late Afternoon"
              },
              {
                "id": 141113185,
                "url": "https://finnhub.io/api/news?id=ffe8f821463a343289a11f64068bcee41cc91dca55356f4a3d50ffb074e8f0f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The healthcare giant showered its owners with cash, yet the stock fell behind. Here is the accounting of what investors actually got and what the trade-off cost them.",
                "category": "company",
                "datetime": 1785871390,
                "headline": "The $85 Billion Consolation Prize For JNJ Shareholders"
              },
              {
                "id": 141109964,
                "url": "https://finnhub.io/api/news?id=6e7f4317cb786b7f9728ee04a233d67a2d9a56a04c50fa6ec2539e7df112e8db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Pharmaceutical company AbbVie (NYSE:ABBV) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 10.2% year on year to $16.99 billion. Its non-GAAP profit of $3.65 per share was 1.2% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785858082,
                "headline": "ABBV Q2 Deep Dive: Immunology and Neuroscience Expansion Shape Outlook Amid Guidance Reset"
              },
              {
                "id": 141109951,
                "url": "https://finnhub.io/api/news?id=e797e0aa936de6b0064211ba2903917ac54b6d9e07c6a92e8357299462acd0fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Merck (MRK) and Pfizer (PFE) raised their respective full-year sales outlooks on Tuesday, as both ph",
                "category": "company",
                "datetime": 1785855413,
                "headline": "Merck, Pfizer Lift Full-Year Sales Outlooks Following Second-Quarter Beats"
              },
              {
                "id": 141111550,
                "url": "https://finnhub.io/api/news?id=de33b8a0123d2b292054ba1f29716341249c010c55f9d5ee0e321353a5057f28",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2212125572/image_2212125572.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "OPKO Health's Q2 results: IP revenue surged on Nicoya deal and FY2026 guidance rose. Click for this OPK stock update.",
                "category": "company",
                "datetime": 1785851748,
                "headline": "OPKO Health: Mazdutide And MDX-2201 Could Change Everything"
              },
              {
                "id": 141108581,
                "url": "https://finnhub.io/api/news?id=da39fad6ce4023618044e99e788b9a7e74dce51c406f6625526fe595c6dd08ef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for BOTOX® Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearance of marked to very marked masseter muscle prominence (MMP) associated with masseter muscle activity in adults. If approved, BOTOX® Cosmetic would become the first and only neurotoxin indicated for this condition in the U.",
                "category": "company",
                "datetime": 1785844800,
                "headline": "Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence"
              },
              {
                "id": 141108544,
                "url": "https://finnhub.io/api/news?id=3ba73eb480f565d3b222d2e26e21c31875414361f708858d97bc10009ca620bb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.",
                "category": "company",
                "datetime": 1785844380,
                "headline": "AstraZeneca-Bristol Myers: The Floodgates for Biotech Mergers Are Open"
              },
              {
                "id": 141107738,
                "url": "https://finnhub.io/api/news?id=6a988a79719d8712b08fec53bd6f03baac19f7d282b1c392dd4b4c8a6b5c4c65",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) announced today that Canada's Drug Agency (CDA-AMC) has recommended UBRELVY® (ubrogepant) be reimbursed with conditions by public drug plans for the acute treatment of migraine, with or without aura, in adults with a history of migraine attacks with moderate to severe pain.3",
                "category": "company",
                "datetime": 1785837660,
                "headline": "UBRELVY® (ubrogepant) Recommended for Reimbursement by Canada's Drug Agency (CDA-AMC) for Acute Migraine Treatment"
              },
              {
                "id": 141110843,
                "url": "https://finnhub.io/api/news?id=7456f8076167e76e77ac5caf63b0ea6b2f0e2b83c1251b773058249c5604dfc8",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "https://www.bloomberg.com/news/articles/2026-08-04/abbvie-seeks-at-least-8-billion-in-debt-to-fund-apogee-deal",
                "category": "company",
                "datetime": 1785835511,
                "headline": "'AbbVie Seeks at Least $8 Billion in Debt to Fund Apogee Deal' - Bloomberg"
              },
              {
                "id": 141110844,
                "url": "https://finnhub.io/api/news?id=bf20c9712d90cc85b1006ad550fb7cc02f567dd543b3dd3c61276130ec7e19c0",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for BOTOX® Cosmetic",
                "category": "company",
                "datetime": 1785830487,
                "headline": "AbbVie's Allergan Aesthetics Receives FDA Acceptance For Review For Its Supplemental Biologics License Application For BOTOX Cosmetic"
              },
              {
                "id": 141110845,
                "url": "https://finnhub.io/api/news?id=5c9038358547dbb1595d9f37867ff7ff82bd64ab691560cd542b554b53dadf2c",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Guggenheim  analyst Vamil Divan   maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $261 to $288.",
                "category": "company",
                "datetime": 1785829730,
                "headline": "Guggenheim Maintains Buy on AbbVie, Raises Price Target to $288"
              },
              {
                "id": 141110846,
                "url": "https://finnhub.io/api/news?id=28a9806e01411afa1527d3c7fecc1579952b1919d1cb985d09f8358c321950b5",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "UBRELVY® (ubrogepant) positive recommendation by Canada's Drug Agency (CDA-AMC) is supported by evidence from the pivotal Phase3 ACHIEVEI and ACHIEVEII studies.CDA-AMC recommendation recognizes the need for",
                "category": "company",
                "datetime": 1785824177,
                "headline": "AbbVie Says Canada's Drug Agency Recommends UBRELVY Be Reimbursed With Conditions By Public Drug Plans For Acute Treatment Of Migraine In Adults"
              },
              {
                "id": 141106141,
                "url": "https://finnhub.io/api/news?id=dbf4b6019f91f02858a1ece648ddae5789111607280907eb8c2c8f7b58dbb7e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.",
                "category": "company",
                "datetime": 1785821400,
                "headline": "More Biotech M&A Is Coming, Whether an AstraZeneca-Bristol Myers Deal Happens or Not"
              },
              {
                "id": 141111671,
                "url": "https://finnhub.io/api/news?id=9b556dc9deb3a11dc5a1c80e204ef78f32d01b2dca5bc25093778d87412b676c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Deal or no deal, mere talks between Astrazeneca and Bristol-Myers point to one of the global pharma industry’s biggest themes.",
                "category": "company",
                "datetime": 1785816060,
                "headline": "‘Huh?’ Markets React to AstraZeneca’s Megadeal Talks With Bristol Myers"
              },
              {
                "id": 141104215,
                "url": "https://finnhub.io/api/news?id=f90be4844bbfd3be905a623ee6e1e0773889b20041c5133207617d9f83f6a119",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The pharmaceutical giant sent shareholders a fortune in cash, yet the stock itself fell far behind the market. Here is the honest accounting of what owners actually got.",
                "category": "company",
                "datetime": 1785798877,
                "headline": "$49 Billion In Payouts, A Lagging Stock: The Pfizer Trade-Off"
              },
              {
                "id": 141102901,
                "url": "https://finnhub.io/api/news?id=d4dad4b699c25939294901b37ea777c978aeb76e6fceb2ae6fa35fdbcd0e2d11",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "SKYRIZI supplies close to a third of guided company revenue, which puts an unusual amount of AbbVie's future behind one patent estate.",
                "category": "company",
                "datetime": 1785791142,
                "headline": "AbbVie's Growth Now Leans On A Single Molecule"
              },
              {
                "id": 141110847,
                "url": "https://finnhub.io/api/news?id=b6fc2459055243ef0a7a91281b2fd5ab1d52157cddc4753f6f8a82c4c3216e65",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Canaccord Genuity  analyst Gary Nachman   maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $282 to $290.",
                "category": "company",
                "datetime": 1785777497,
                "headline": "Canaccord Genuity Maintains Buy on AbbVie, Raises Price Target to $290"
              },
              {
                "id": 141100779,
                "url": "https://finnhub.io/api/news?id=e3ca59cf6e34e30471a6601a0ba277a531ad295e5dc8b9b29bb5937fd95a3983",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The esophageal cancer market landscape is poised for substantial transformation with the introduction of innovative therapeutic approaches, including antibody-drug conjugates (ADCs), next-generation targeted therapies, and combination immunotherapy regimens. Emerging candidates such as Telisotuzumab adizutecan (AbbVie) highlight this progress by delivering cytotoxic agents directly to tumor cells with greater precision.New York, USA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Esophageal Cancer Market to",
                "category": "company",
                "datetime": 1785776400,
                "headline": "Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026–2036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight"
              },
              {
                "id": 141111662,
                "url": "https://finnhub.io/api/news?id=6e71450bdf5b7604e689e41936a1f88574d1e3d7cf4c5df85452b935df8a116d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "As the NASDAQ-100 corrects amid an AI CapEx-driven tech sell-off, sectors like healthcare and financials are rallying, boosting diversified value ETFs like the Schwab U.S. Large-Cap Value ETF (SCHV).",
                "category": "company",
                "datetime": 1785775200,
                "headline": "The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure"
              },
              {
                "id": 141100727,
                "url": "https://finnhub.io/api/news?id=93beca83add4b02ad8b271b7b1ba0242659fa4ae9be591f4bd91c8198b9827db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.",
                "category": "company",
                "datetime": 1785773653,
                "headline": "Stocks mixed as AstraZeneca merger talk dents FTSE 100"
              },
              {
                "id": 141104231,
                "url": "https://finnhub.io/api/news?id=f5640ff67b7f0dff8d4acb32c1dad754ffcea965097e85d4f8866ff61c150b05",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Despite AbbVie’s outperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.",
                "category": "company",
                "datetime": 1785772900,
                "headline": "What Are Wall Street Analysts' Target Price for AbbVie Stock?"
              },
              {
                "id": 141100781,
                "url": "https://finnhub.io/api/news?id=af315b5b99b89c0c23ee46c049e3ac334340df5fe0be3a197bed9cfea6d9969e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) reported another \"strong\" quarter operationally, with investor attention increasingly",
                "category": "company",
                "datetime": 1785772552,
                "headline": "AbbVie Pipeline Draws Greater Investor Focus After 'Strong' Q2, RBC Says"
              },
              {
                "id": 141104216,
                "url": "https://finnhub.io/api/news?id=d77b4af73a0ae6b155f2e7af6fd9eb9d1432425df71bb6ac044b62a72ae183e4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "IPO Edge hosted a fireside chat with Conexeu Sciences Inc. (Nasdaq: CNXU) President and Chief Executive Officer Miles Harrison, moderated by IPO Edge Editor-in-Chief John Jannarone and Editor-at-Large Jarrett Banks in a […]",
                "category": "company",
                "datetime": 1785768954,
                "headline": "Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison"
              },
              {
                "id": 141100782,
                "url": "https://finnhub.io/api/news?id=e60fb40d8554b9209556b6ebff14bc51e6b44d0abf62a249f1194ef641a11e7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie raises 2026 revenue guidance on Skyrizi, Rinvoq and neuroscience growth, while the Apogee deal trims EPS guidance and lifts R&D spending.",
                "category": "company",
                "datetime": 1785765600,
                "headline": "ABBV Q2 Earnings Call Balances Growth With Apogee Dilution"
              },
              {
                "id": 141110823,
                "url": "https://finnhub.io/api/news?id=59536925328acfcf2795e77fa358abce85166756e7bdad705b2881275bc525f0",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/03/Merger-And-Acquisition-Business-Corporat.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AstraZeneca and Bristol Myers reportedly discuss a $400 billion merger as analyst assesses valuation, patent risks and regulatory hurdles.",
                "category": "company",
                "datetime": 1785762819,
                "headline": "AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus"
              },
              {
                "id": 141098760,
                "url": "https://finnhub.io/api/news?id=295300f8195581d504cda12b4ff55830b229bb2bd3b6d33c887afd23ad24ee10",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Your portfolio could be paying you quarterly income right now from three companies that have raised their dividends for decades straight, but the next ex-dates are approaching fast and missing them means waiting another quarter to collect.",
                "category": "company",
                "datetime": 1785760259,
                "headline": "3 Top Dividend Stocks to Buy Before Their Next Payout"
              },
              {
                "id": 141099326,
                "url": "https://finnhub.io/api/news?id=cc2662e857815e4ce5bff63b03718501328f075fffcc39c614651be14387b757",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2156417320/image_2156417320.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "AbbVie Inc. stock fell 6.2% after a 52-week high despite strong Q2 earnings; Rinvoq and Elahere sales surged. Click for this ABBV earnings udpate.",
                "category": "company",
                "datetime": 1785751531,
                "headline": "AbbVie: Strong Q2 And New Catalysts Keep Me Bullish"
              },
              {
                "id": 141100269,
                "url": "https://finnhub.io/api/news?id=d909bb1dbbac5c954ada51e140db524a33f0b187ed642a0056c443ac1d48cd64",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Cantor Fitzgerald  analyst Carter Gould   maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $265 to $285.",
                "category": "company",
                "datetime": 1785746814,
                "headline": "Cantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $285"
              },
              {
                "id": 141100783,
                "url": "https://finnhub.io/api/news?id=cf9b73def0f1a76b11756132579876cdade6b5662526983f33abbb87f575f3f2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie posted strong Q2 revenue and EPS growth, and despite a post-earnings dip tied to the Apogee Therapeutics deal, analysts and dividend strength support shares reaching $300.",
                "category": "company",
                "datetime": 1785682800,
                "headline": "AbbVie Quietly Solved Its Biggest Problem—Now What?"
              },
              {
                "id": 141084258,
                "url": "https://finnhub.io/api/news?id=8f647e1c9b87d7a0145a50ec9121f690d7715f4964a424b15a582e40e09291e5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The company, one of the rare healthcare sector Dividend Kings, wasn't looking too royal on the last trading day of the week.",
                "category": "company",
                "datetime": 1785542481,
                "headline": "Why AbbVie Stock Slumped Today"
              },
              {
                "id": 141082601,
                "url": "https://finnhub.io/api/news?id=65c6bb9a48a8a6767c6d8ec539b3c82814034592c097522a8ce51873039f8ab0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) received European Commission approval for RINVOQ (upadacitinib) as the first systemic treatment in the EU for non segmental vitiligo. The decision also covers RINVOQ as a systemic option for severe alopecia areata in adults and adolescents. These approvals expand RINVOQ’s labeled uses in Europe and add new indications in dermatology and immunology. For investors following AbbVie, this move adds fresh detail to the story around its immunology franchise. The company...",
                "category": "company",
                "datetime": 1785532221,
                "headline": "AbbVie (ABBV) Wins EU Approval For RINVOQ In Vitiligo And Alopecia"
              },
              {
                "id": 141082602,
                "url": "https://finnhub.io/api/news?id=3c2eafd52a67ba1afd7b285cc44856f94f72f58d43ea6fe3f5e1fff4217847eb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie Inc (ABBV) beats expectations with 10.2% revenue growth, raises full-year guidance, and showcases promising pipeline developments despite Humira's decline.",
                "category": "company",
                "datetime": 1785531661,
                "headline": "AbbVie Inc (ABBV) (Q2 2026) Earnings Call Highlights: Robust Growth Driven by Skyrizi and ..."
              },
              {
                "id": 141081525,
                "url": "https://finnhub.io/api/news?id=21af69931f0ca29d34869ccbb2de126b8102a3e78424cef591d53d9c6d3cdd39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie slashes its full-year guidance to account for its pending acquisition of Apogee Therapeutics.",
                "category": "company",
                "datetime": 1785518520,
                "headline": "AbbVie Earnings Beat Forecasts as Skyrizi Sales Soar 24%. Why the Stock Is Falling."
              },
              {
                "id": 141082293,
                "url": "https://finnhub.io/api/news?id=47bdb4f92c4fcd1ac1e342ca45dd31e6bd1624882562a0dd56dddf3ee970f21b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1391441819/image_1391441819.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Viatris is rated a Sell due to persistent risks, weak financials, and a likely profit-taking event post-Q2 2026 earnings. Read more on VTRS stock here.",
                "category": "company",
                "datetime": 1785518138,
                "headline": "Low Growth Viatris Is Due For A Pullback After A Stellar 16-Month Run"
              },
              {
                "id": 141081519,
                "url": "https://finnhub.io/api/news?id=092378f14fbaf65df765133c573286e97c0df60a3952b635aafd21dc6def0b1c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie tops Q2 earnings and revenue estimates on strong immunology drug sales, but a lower 2026 EPS outlook tied to the Apogee deal weighs on shares.",
                "category": "company",
                "datetime": 1785517860,
                "headline": "ABBV Beats on Q2 Earnings & Sales, Cuts '26 EPS View, Stock Down"
              },
              {
                "id": 141080313,
                "url": "https://finnhub.io/api/news?id=cf326811101db0e4abbede08efd4c6c0943d35e213367c69ebda4a76b979e103",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Moby summary of AbbVie Inc.'s Q2 2026 earnings call",
                "category": "company",
                "datetime": 1785516659,
                "headline": "AbbVie Inc. Q2 2026 Earnings Call Summary"
              },
              {
                "id": 141081925,
                "url": "https://finnhub.io/api/news?id=bf085e574bf0c493b0803a1456001c8a53278d8a528a8003314889bb252732ab",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "AbbVie Inc. (ABBV) Q2 2026 Earnings Call July 31, 2026 9:00 AM EDTCompany ParticipantsElizabeth Shea - Senior Vice President of Investor RelationsRobert...",
                "category": "company",
                "datetime": 1785515013,
                "headline": "AbbVie Inc. (ABBV) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141080308,
                "url": "https://finnhub.io/api/news?id=3c4393408a8fd4ee84090b505d6f9b4c7f4085acb7a7f867e6203122edc98ac5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Stocks rose in midday trading Friday, erasing earlier losses as investors assessed earnings from maj",
                "category": "company",
                "datetime": 1785513926,
                "headline": "Top Midday Stories: Apple Shares Fall on Weak Guidance; Amazon Q2 EPS Beats Estimates as AWS Sales Surge"
              },
              {
                "id": 141083123,
                "url": "https://finnhub.io/api/news?id=2db5f0a66870fda68bc9aa8df97e26f93d72a67888ce2ee1e469341d119c13ac",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_4.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 5.65% on an annualized basis producing an average annual return of 16.8%. Currently, AbbVie has a market capitalization of $436.27 billion. \nBuying",
                "category": "company",
                "datetime": 1785513643,
                "headline": "Here's How Much $1000 Invested In AbbVie 5 Years Ago Would Be Worth Today"
              },
              {
                "id": 141080311,
                "url": "https://finnhub.io/api/news?id=065f4a1a3bb93cd6a66fec993d61203ed8bd6bcd95a567c41c0bd878c2cd24c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) lowered its full-year earnings guidance on Friday to account for the expected dilution",
                "category": "company",
                "datetime": 1785512731,
                "headline": "AbbVie Trims Full-Year Profit Outlook Due to Apogee Acquisition"
              },
              {
                "id": 141080309,
                "url": "https://finnhub.io/api/news?id=8a3534bd4009b69a71a93dd71f5bba954daf75fe76084b26305e55bb39330da3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Earnings Data Deluge",
                "category": "company",
                "datetime": 1785511680,
                "headline": "Earnings Data Deluge"
              },
              {
                "id": 141078975,
                "url": "https://finnhub.io/api/news?id=35c14c210bf3b2f190b4af5c8b89d12f9f05e9c2d5091050cb7bd375e52ef2e0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) reported second-quarter 2026 results that exceeded its expectations, supported by double-digit growth in its immunology and neuroscience businesses, and raised its full-year revenue outlook by $300 million. Chairman and Chief Executive Officer Rob Michael said adjusted earnings p",
                "category": "company",
                "datetime": 1785510268,
                "headline": "AbbVie Q2 Earnings Call Highlights"
              },
              {
                "id": 141078976,
                "url": "https://finnhub.io/api/news?id=b7d97bc3de80d7b59d4f09531b8def1b8ecf3cf0334ce71e784415c96c37dc5e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Revenue of $16.99 billion and adjusted EPS of $3.65 both beat estimates",
                "category": "company",
                "datetime": 1785510228,
                "headline": "AbbVie Beats but Cuts Guidance on $10.9 Billion Acquisition"
              },
              {
                "id": 141078967,
                "url": "https://finnhub.io/api/news?id=2f80b7fd914d4836dd5732378c775b0167fc597642d185d22ef40c9454c93646",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Despite some mid-week turbulence, we're trading fairly even with where we were as of mid-day Monday.",
                "category": "company",
                "datetime": 1785508440,
                "headline": "Pre-Market Trading Up in Final Session of the Week"
              },
              {
                "id": 141078938,
                "url": "https://finnhub.io/api/news?id=904056145b3b700f5b4951a026912ba2b2f2d20293cb187a0d707165b290f859",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Eli Lilly stock ran on a story that was public and dated long before the price moved, and reading it right still would not have put you ahead of every peer.",
                "category": "company",
                "datetime": 1785507981,
                "headline": "The Signs Before Eli Lilly Stock Surged Were All On The Record"
              },
              {
                "id": 141078939,
                "url": "https://finnhub.io/api/news?id=6fcc1f678f181e34376a4202dbe1cd843f51aa42067d5392c634aac3c29f9081",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Here is a way to get paid a meaningful income now on your Eli Lilly shares, income you keep no matter what the stock does, in exchange for agreeing to sell at a price above today's if it climbs there.",
                "category": "company",
                "datetime": 1785506858,
                "headline": "LLY Stock: Collect 12% Now, In Exchange For Capping Upside At 15%"
              },
              {
                "id": 141078980,
                "url": "https://finnhub.io/api/news?id=014831428409dbba11f5692e6c73b19da31aeaa3a7ac48ece993985543f27214",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The headline numbers for AbbVie (ABBV) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
                "category": "company",
                "datetime": 1785506402,
                "headline": "AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates"
              },
              {
                "id": 141080716,
                "url": "https://finnhub.io/api/news?id=400c1e253059928ecd67705b55506f50b8f112b556e3bea7f2de09df91a3664f",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/31/Amazon-Logo-On.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Amazon surges 15% on an AWS blowout while Apple sheds nearly $475 billion in value. Yields sit at cycle highs.",
                "category": "company",
                "datetime": 1785505365,
                "headline": "Stock Market Today: Amazon Jumps 15%, Apple Wipes Out $475 Billion"
              },
              {
                "id": 141083125,
                "url": "https://finnhub.io/api/news?id=124c8531440585f041703b9413c14bc51c8da14ba7b5e2d00644609cd0ab8751",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/31/Ipo-Initial-Public-Offering--Business-Ma.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Moleculin Biotech updates MIRACLE trial for AML and prices a $9.3M offering at $0.75, driving MBRX shares down 63%. Read full data.",
                "category": "company",
                "datetime": 1785505029,
                "headline": "Moleculin Biotech Stock Is Sinking Friday: What's Going On?"
              },
              {
                "id": 141077988,
                "url": "https://finnhub.io/api/news?id=1ca075bc1a56b6dcf424fd797aa4ffc47a3c2f453052f6faf045443e0afb79f6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The drugmaker beat second-quarter estimates on strong immunology sales but lowered its full-year adjusted earnings outlook by 14 cents a share",
                "category": "company",
                "datetime": 1785504002,
                "headline": "AbbVie Q2 2026 earnings: profit forecast cut for Apogee deal"
              },
              {
                "id": 141077989,
                "url": "https://finnhub.io/api/news?id=b3ee4a487bdd88722763b035259a6f911b58e271a762fbda286221ae3b9b4be8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Pharmaceutical company AbbVie (NYSE:ABBV) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.2% year on year to $16.99 billion. Its non-GAAP profit of $3.65 per share was 1.2% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785502779,
                "headline": "AbbVie’s (NYSE:ABBV) Q2 CY2026: Beats On Revenue"
              },
              {
                "id": 141078981,
                "url": "https://finnhub.io/api/news?id=463a69dba7aff2143b11d7e08a0df0d5a21fc293541a944b75ac8b355e0243ab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) delivered earnings and revenue surprises of +0.28% and +1.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785502502,
                "headline": "AbbVie (ABBV) Q2 Earnings and Revenues Beat Estimates"
              },
              {
                "id": 141077867,
                "url": "https://finnhub.io/api/news?id=84f0275a275618ec204a5a85015de38502cbd34f3bc57cbee2dc1cd924dd6bc9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "(Updates with economic data, recent oil price movement, world markets' overview and corporate stock",
                "category": "company",
                "datetime": 1785502028,
                "headline": "Update: Amazon Overperformance Lifts US Equity Futures Pre-Bell Amid Potential Expansion of Middle East Conflict to Egypt"
              },
              {
                "id": 141077642,
                "url": "https://finnhub.io/api/news?id=3223cbf246df2f33c69539037f774a50260cd33d10286f045a518ad8062cad57",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "ABBV",
                "summary": "Discover the top S&P500 movers in Friday's pre-market session and stay informed about market dynamics.",
                "category": "company",
                "datetime": 1785501301,
                "headline": "Get insights into the top movers in the S&P500 index of Friday's pre-market session."
              },
              {
                "id": 141077991,
                "url": "https://finnhub.io/api/news?id=a72a9ef1f80c49cf023dc84c5c3fbc9b8cd68aa14f354e2826cb1f446f3ee4b1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie  shares took a hit Friday after costs related to the drugmaker’s acquisition of Apogee Therapeutics forced a cut to its full-year profit outlook.  Second-quarter revenue jumped 10% to nearly $17 billion, beating the $16.8 billion consensus estimate among analysts polled by FactSet.  AbbVie  posted adjusted earnings of $3.65 a share, narrowly ahead of Wall Street’s call for $3.60.",
                "category": "company",
                "datetime": 1785501060,
                "headline": "AbbVie Bought Apogee to Strengthen Its Portfolio. Now It’s Cutting Earnings Guidance."
              },
              {
                "id": 141077992,
                "url": "https://finnhub.io/api/news?id=8ecf5c62b72c4d15c0daf04bb83e4bedff34a151a5bb146c221727b9ff2d389c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Investing.com -- AbbVie Inc. (NYSE: ABBV) reported second-quarter earnings before the open on Friday, missing profit expectations, although revenue beat the consensus estimate.",
                "category": "company",
                "datetime": 1785500834,
                "headline": "AbbVie shares fall on earnings miss and weak guidance"
              },
              {
                "id": 141077567,
                "url": "https://finnhub.io/api/news?id=29cd62e5bcd61d77eb45ae5acdd626e987475550af11a1b82822076dbcce5389",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_16_065e226ebd.webp",
                "source": "ChartMill",
                "related": "ABBV",
                "summary": "AbbVie Q2 earnings match estimates, but stock dips 4% on Apogee Therapeutics acquisition news amid steady results.",
                "category": "company",
                "datetime": 1785500429,
                "headline": "AbbVie (NYSE:ABBV) Shares Slip on Apogee Acquisition Despite In-Line Q2 Results"
              },
              {
                "id": 141077109,
                "url": "https://finnhub.io/api/news?id=f16d5a2dc9b6a4824034e9a6c0d771a4a457d491209a6f45740cd61bdbd2cfc4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The benchmark US stock measures were tracking in the green before the open Friday as Amazon's (AMZN)",
                "category": "company",
                "datetime": 1785498389,
                "headline": "Stocks Rise Pre-Bell as Amazon Results Lift AI Trade Sentiment"
              },
              {
                "id": 141083126,
                "url": "https://finnhub.io/api/news?id=83fc956e5a4b5a60210f7dcb4a0d129e7ab44a033462a71256b10e75d4b2423c",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) is looking for Q3 Adj EPS of $3.84-$3.88 vs $3.84 analyst estimate. sees sales of $17.200 billion vs $17.322 billion analyst estimate.",
                "category": "company",
                "datetime": 1785497257,
                "headline": "Conference Call:\nAbbVie Sees Q3 Adj EPS $3.84-$3.88 vs $3.84 Est; Sees Sales $17.200B vs $17.322B Est"
              },
              {
                "id": 141083127,
                "url": "https://finnhub.io/api/news?id=c2401c82c6bbe855e37c2157755df80079151eef2330f3f3b29d915bc8f56a3d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/31/Abbvie.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie Inc. (NYSE: ABBV) shares are retreating Friday after trimming full-year adjusted EPS guidance below analyst targets.",
                "category": "company",
                "datetime": 1785492987,
                "headline": "AbbVie Stock Falls as Guidance Cut Overshadows Strong Q2 Earnings Beat"
              },
              {
                "id": 141083128,
                "url": "https://finnhub.io/api/news?id=d31424c1a9ba8afbb685c81cb6bb3d4767b218c2adb1757bb2c9fa154f145771",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "https://edge.media-server.com/mmc/p/m9vcn44b/",
                "category": "company",
                "datetime": 1785490226,
                "headline": "AbbVie Exec Says Now Expect Total Annual Net Revenue Of ~$67.6B, Increase Of $300M Versus Previous Forecast"
              },
              {
                "id": 141083129,
                "url": "https://finnhub.io/api/news?id=fd9e6b6226975918e236eeac92f55ceefcf946ab34c4ff5eda4218a4f37a5b1a",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) lowers FY2026 Adj EPS guidance from $13.91-$14.11 to $13.87-$14.07 vs $14.08 analyst estimate..",
                "category": "company",
                "datetime": 1785486104,
                "headline": "CORRECTION: AbbVie Lowers FY2026 Adj EPS Guidance from $13.91-$14.11 to $13.87-$14.07 vs $14.08 Est"
              },
              {
                "id": 141083130,
                "url": "https://finnhub.io/api/news?id=26e10aae59e7b01e8e02d1c8556f4a0c9f09a7781d9f9dab351b59b001e855ac",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) reported quarterly earnings of $3.65 per share which beat the analyst consensus estimate of $3.60 by 1.39 percent. This is a 22.9 percent increase over earnings of $2.97 per share from the same period",
                "category": "company",
                "datetime": 1785484121,
                "headline": "AbbVie Q2 Adj. EPS $3.65 Beats $3.60 Estimate, Sales $16.990B Beat $16.765B Estimate"
              },
              {
                "id": 141072918,
                "url": "https://finnhub.io/api/news?id=14dc8fa65654e512f70d4fda3e23e46128c2ac9e31b7c4e11adb51ad16cd7269",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Asking for a Trend Host Josh Lipton previews what investors should be on the lookout for on Friday, July 31, including earnings from energy giants Exxon (XOM), Chevron (CVX), and biopharma AbbVie (ABBV) as well as the latest read on consumer sentiment.",
                "category": "company",
                "datetime": 1785448860,
                "headline": "Friday's market movers: Oil earnings and consumer sentiment data"
              },
              {
                "id": 141066701,
                "url": "https://finnhub.io/api/news?id=6c58f0d6da027f5209d141c1ef2370eb95d32ae48782c108da3d5b120b00ed88",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Rinvoq, Comirnaty and Opzelura have all received their own EC approvals this week.",
                "category": "company",
                "datetime": 1785423940,
                "headline": "EU regulatory roundup: AbbVie, Pfizer & BioNTech and Incyte net approvals"
              },
              {
                "id": 141066702,
                "url": "https://finnhub.io/api/news?id=c1a81224db58e623178488a479aee7585a58116ec82004d3c0df2ac88b00d9bd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Pharmaceutical company AbbVie (NYSE:ABBV) will be announcing earnings results this Friday before market hours. Here’s what to look for.",
                "category": "company",
                "datetime": 1785420302,
                "headline": "What To Expect From AbbVie’s (ABBV) Q2 Earnings"
              },
              {
                "id": 141064881,
                "url": "https://finnhub.io/api/news?id=8ee9be09420ca3ed72c8b63e7edf7b20b0f876a3dfc6832ec20215871d382e2d",
                "image": "https://www.chartmill.com/images/uploads/cannabis_theme_f843462963.webp",
                "source": "ChartMill",
                "related": "ABBV",
                "summary": "While pure-play cannabis stocks struggle, defensive opportunities emerge in pharma, staples, and industrial firms like AbbVie, Altria, and Jazz Pharma with strong profitability and value.",
                "category": "company",
                "datetime": 1785413140,
                "headline": "Cannabis Theme's Hidden Strength: Established Players Outshining Pure Plays"
              },
              {
                "id": 141065442,
                "url": "https://finnhub.io/api/news?id=5f513d8aac12ed99fa2513604c134eec1c8eaf449e3e76734d40195a638efb9e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the return of JUVÉDERM® Day on Wednesday, August 19, 2026, with exclusive JUVÉDERM® offers for Allē Members. Allergan Aesthetics invites aesthetic providers and consumers to join in celebrating JUVÉDERM®'s continued aesthetics leadership as the number one chosen hyaluronic acid (HA) dermal filler collection in the U.S.*,1",
                "category": "company",
                "datetime": 1785412800,
                "headline": "JUVÉDERM® Day Returns to U.S. on August 19"
              },
              {
                "id": 141058324,
                "url": "https://finnhub.io/api/news?id=15c4df4c5fb54cf1ba96872499789cc422bc41568843a346462416b65eec3566",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "But is that performance sustainable?",
                "category": "company",
                "datetime": 1785360000,
                "headline": "Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now"
              },
              {
                "id": 141057017,
                "url": "https://finnhub.io/api/news?id=e2cfd77352aedb0d87503712841214980f53bb4ab61b29927df9b64aee78b575",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The sticker shock on the pharma giant's shares fades once you look at what investors are paying for the earnings expected just two years from now.",
                "category": "company",
                "datetime": 1785348670,
                "headline": "The Real Price of AbbVie Stock Is Cheaper Than You Think"
              },
              {
                "id": 141055722,
                "url": "https://finnhub.io/api/news?id=6344153d97a5d0b9c3e6164f8d007b3dc14a32a4ecff0263cc00d944695d9d8a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie still looks like a compelling buy at its all-time high.",
                "category": "company",
                "datetime": 1785344178,
                "headline": "AbbVie Has Raised Its Dividend for 53 Straight Years and Still Looks Attractively Valued. Is This Dividend King the Smartest Buy in Healthcare Right Now?"
              },
              {
                "id": 141051551,
                "url": "https://finnhub.io/api/news?id=52069f3a25acd2269ac3042a98b22b4096429e52957c77caa9a9c2ca47b141c8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie stock has delivered strong returns over the past five years, yet the current valuation picture is split, with the intrinsic value estimate pointing to upside while market multiples suggest the shares screen rich. AbbVie has returned 172.0% over five years, which puts extra focus on whether the current price still offers an attractive entry for new capital. Recent European approvals for RINVOQ and Allergan Aesthetics' Boey can support expectations for future cash flows, while mixed...",
                "category": "company",
                "datetime": 1785316228,
                "headline": "AbbVie (ABBV) Stock May Be Mispriced On Its 172% Run"
              },
              {
                "id": 141058776,
                "url": "https://finnhub.io/api/news?id=dfd3cd04cb31c055bb002756e92c7825d34d1fdcdb9c60dbd0bc06d6265c8057",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Barclays  analyst Emily Field   maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $275 to $300.",
                "category": "company",
                "datetime": 1785311580,
                "headline": "Barclays Maintains Overweight on AbbVie, Raises Price Target to $300"
              },
              {
                "id": 141051094,
                "url": "https://finnhub.io/api/news?id=3362d57cf865944f735f12e8966b6a1467613672ba4d1ef0d145a4d4a6a0c324",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients 12 years and older with severe alopecia areata (AA).1",
                "category": "company",
                "datetime": 1785308400,
                "headline": "AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata"
              },
              {
                "id": 141051093,
                "url": "https://finnhub.io/api/news?id=5541ab38e7cdf3061e53354715cd59a6ef9646e8707eee436a81ad24d2a0f068",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of adult and adolescent patients 12 years and older with non-segmental vitiligo (NSV) who are candidates for systemic therapy.1 With this approval, RINVOQ is now the first and only systemic medication approved in the European Union for NSV, the most common form of vitiligo.2",
                "category": "company",
                "datetime": 1785308400,
                "headline": "AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo"
              },
              {
                "id": 141057973,
                "url": "https://finnhub.io/api/news?id=d2cd32fbbfda3153a0cde8cbe47e51cc4aecd15c201ffdd168c8fb785d2c51b8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/29/Dallas--Tx---August-5--2022-Senator-Rick.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Scott warns China’s new drug rules could threaten U.S. medicine security, urging America to reduce reliance on Beijing.",
                "category": "company",
                "datetime": 1785307896,
                "headline": "Rick Scott Warns Beijing's New Drug Rules Could Threaten US Medicine Supply: 'Stop Being Dependent on Communist China'"
              },
              {
                "id": 141049956,
                "url": "https://finnhub.io/api/news?id=c11f70f6248138fa74face27e195c6ee05be83507d3b26659819389f8909ebe7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie(ABBV) reports second-quarter results on Friday, July 31, and the mood around the stock has changed. A few months ago, investors were restless. The two drugs carrying the company were doing fine, but everyone already knew that, and the market wanted a new reason to invest. Goldman Sachs went ...",
                "category": "company",
                "datetime": 1785295980,
                "headline": "Goldman Sachs uncovers key AbbVie stock signals before earnings"
              },
              {
                "id": 141058778,
                "url": "https://finnhub.io/api/news?id=fb06d7ab57159e178e0b2a19e257ef34df38d0c33567258a7e8ec4372b4bb027",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV)The approval is supported by data from the Phase 3 Viti-Up clinical",
                "category": "company",
                "datetime": 1785294337,
                "headline": "AbbVie's RINVOQ Wins European Commission Approval For Non-Segmental Vitiligo, First Systemic Medication Approved In EU For This Condition"
              },
              {
                "id": 141047303,
                "url": "https://finnhub.io/api/news?id=556426890a3fac26e5447912eb362cc02010df281b0dcb32f90c4409a7a36c9e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Johnson & Johnson stock's oncology engine and its steady guidance raises were on the record quarters before the price moved.",
                "category": "company",
                "datetime": 1785271965,
                "headline": "What Johnson & Johnson Stock Told You Before It Surged"
              },
              {
                "id": 141047304,
                "url": "https://finnhub.io/api/news?id=964cb7fb943f3d27b92bfa4cd03543b70ad5d97017a3e0c9b5c997db08924eeb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "One of the market's strongest health care performers barely moves with the index you already own, and that gap is the whole point.",
                "category": "company",
                "datetime": 1785271282,
                "headline": "Does Eli Lilly Stock Actually Diversify Your Portfolio?"
              },
              {
                "id": 141046317,
                "url": "https://finnhub.io/api/news?id=94ec934ac7182b360928921fb093fe8b32d0201037b531cdc375e9de346bca87",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie closed above the 230.47 buy point from a cup-with-handle base on June 23 and has climbed 15% from there.  The previous day, the stock jumped more than 6% after AbbVie announced it agreed to acquire Apogee Therapeutics.  The $10.9 billion deal would strengthen AbbVie's immunology pipeline.",
                "category": "company",
                "datetime": 1785264011,
                "headline": "Botox Maker Tops Buy Point, But Here Comes The Earnings Report"
              },
              {
                "id": 141045221,
                "url": "https://finnhub.io/api/news?id=aed8f8ea06ef7fad60e0a5b472bd22b69426b946331c27e18ddba12db744ec24",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie's two newest drugs are growing so fast they've rewritten the company's entire story, and Wall Street may not have fully priced in what happens when the July 31 earnings report confirms it.",
                "category": "company",
                "datetime": 1785258596,
                "headline": "3 Major Reasons for Investors to Buy AbbVie Stock Before July 31st"
              },
              {
                "id": 141046312,
                "url": "https://finnhub.io/api/news?id=c28aa1c884cffdf993088c8b520ca68dbb6e087a14c00a11fcf3e0a0dd7be102",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie heads into Q2 earnings with Skyrizi and Rinvoq driving growth as investors weigh Humira declines and the company's long-term outlook.",
                "category": "company",
                "datetime": 1785258360,
                "headline": "Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?"
              },
              {
                "id": 141044381,
                "url": "https://finnhub.io/api/news?id=d30853e65c00378415d30d59a5967ff2f900939f6907ae3ee97252353d3efa08",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "DGRO markets itself as a sleepy dividend fund, but its rulebook quietly funnels money toward mega-cap tech, and the compounding math behind that combination may rewrite which ETF actually wins over the next decade.",
                "category": "company",
                "datetime": 1785254149,
                "headline": "Prediction: This ‘Boring’ Dividend ETF Secretly Rides the AI Trade and Out-Earns Your High-Yield Fund by 2036"
              },
              {
                "id": 141043605,
                "url": "https://finnhub.io/api/news?id=a4e736a3943de92c3e20fe48a9e14561506db203f58dc45385bcab5c4e89fedc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.",
                "category": "company",
                "datetime": 1785247620,
                "headline": "Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?"
              },
              {
                "id": 141043613,
                "url": "https://finnhub.io/api/news?id=40990baf1b73620c80138e2cefd638ab9f0b8ee3c0eb323e7f8610f9347c1f7c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1785247218,
                "headline": "Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release"
              },
              {
                "id": 141042267,
                "url": "https://finnhub.io/api/news?id=8eb48457e30ed759574902fad91ecc34d75054fa92fff08f027b6ddf02e62c26",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1329696857/image_1329696857.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Incyte Corporation stock hits a 52-week high on latarcibart and strong Opzelura/Zynyz sales, but valuation & Iclusig demand drive a Hold. Click for an INCY update.",
                "category": "company",
                "datetime": 1785231217,
                "headline": "Incyte: From Buy To Hold After A 93% Rally (Rating Downgrade)"
              },
              {
                "id": 141038095,
                "url": "https://finnhub.io/api/news?id=2f54abc41486df4873af5700d58fb334ed98a0a9651628208a2a7a80f3b0f840",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The recent rally could pave the way for \"sell the news\" volatility, but don't let this scare you out of a long-term position.",
                "category": "company",
                "datetime": 1785193500,
                "headline": "Should You Buy AbbVie Stock Hand Over Fist Before July 31?"
              },
              {
                "id": 141037135,
                "url": "https://finnhub.io/api/news?id=f039384443066be35bc6ced345a619fa1e6911431bbd02d74d2a8573ae541097",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The drugmaker's rapid stock gains have led to a premium valuation, forcing investors to question its capacity for future growth.",
                "category": "company",
                "datetime": 1785182092,
                "headline": "The Engine Behind ABBV Stock Has Real Parts"
              },
              {
                "id": 141037136,
                "url": "https://finnhub.io/api/news?id=1962630925adf572941ee3d09545871641e85445ce685d06cecba1d3bddbddb1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "UNH's post-earnings pullback follows a 52-week high, as stronger guidance offsets Medicaid pressures and spotlights healthcare ETFs with sizable exposure.",
                "category": "company",
                "datetime": 1785180480,
                "headline": "UnitedHealth Pulls Back Post 52-Week High: Healthcare ETFs to Watch"
              },
              {
                "id": 141036037,
                "url": "https://finnhub.io/api/news?id=2cc61cdbabe57465c6369f88d1cd57b760ec36da2bc51946d6d2f08f0584f756",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Here is a way to get paid a significant income stream today from Eli Lilly stock, which you keep no matter what, while setting a price far below current levels where you would be willing to buy.",
                "category": "company",
                "datetime": 1785177225,
                "headline": "Collect 9.8% On LLY Stock Now, Own It 30% Cheaper If It Dips"
              },
              {
                "id": 141035012,
                "url": "https://finnhub.io/api/news?id=ea501f01f1f94e7fc4f83cb68bde7d8193d75c7629f1a619e9a4ba20eeb05a5f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "S&P 500 companies' second-quarter earnings growth reached 70%, driven by the information technology",
                "category": "company",
                "datetime": 1785172570,
                "headline": "S&P 500 Second-Quarter Earnings Growth Reaches 70%, Oppenheimer Says"
              },
              {
                "id": 141033665,
                "url": "https://finnhub.io/api/news?id=226e97769226d352193ee468abc933e80443ec0634412daea81166b5b2cba6ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "A 2.8% Social Security raise barely covers a trip to the grocery store, so retirees are quietly rebuilding their paychecks around five dividend stocks with track records stretching back through every recession of the past two decades.",
                "category": "company",
                "datetime": 1785166830,
                "headline": "Forget Social Security: 5 Sleep-at-Night Dividend Stocks Retirees Are Using to Replace a Paycheck"
              },
              {
                "id": 141032906,
                "url": "https://finnhub.io/api/news?id=f0d659a1185e8bf25d2be2fd5742b5689573b66b302e1d77ed50a29c82a6f20b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "CAMBRIDGE, Mass., July 27, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition.",
                "category": "company",
                "datetime": 1785155400,
                "headline": "Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer"
              },
              {
                "id": 141033829,
                "url": "https://finnhub.io/api/news?id=f44986411b5d5c5246d9ff515ae37c06ae04189d71b1cbe690556f104ea78a28",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Most recently the leader of buzzy startup Tessera Therapeutics, Severino will look to improve the fortunes of a company facing emerging competition and declining sales for its prized gene therapy Elevidys.",
                "category": "company",
                "datetime": 1785147360,
                "headline": "Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO"
              },
              {
                "id": 141031076,
                "url": "https://finnhub.io/api/news?id=62173fbda2301693a92f3d5da56390b4ea3db8e08c290385b475eabf6e1d5a7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The company that used to reassure you with its sheer breadth now leads with a push to dominate oncology, and a holder who bought a diversified compounder should notice the bet has changed shape.",
                "category": "company",
                "datetime": 1785135053,
                "headline": "Johnson & Johnson Now Leads Its Pitch With An Oncology Bet"
              },
              {
                "id": 141028474,
                "url": "https://finnhub.io/api/news?id=9a2687b22714d8cedc636831b2bc62592056cb84c4baeb1b206ee7ea9c167dc4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2209914068/image_2209914068.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Dividend Kings beat SPY in June–July, reclaiming a YTD lead.",
                "category": "company",
                "datetime": 1785093714,
                "headline": "Best Dividend Kings: July 2026"
              },
              {
                "id": 141023888,
                "url": "https://finnhub.io/api/news?id=0e7c8b9ce48492e0870a97c7e8778cdbf2f0ff180e2b5db500c5b8c844969d64",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Both have very promising futures.",
                "category": "company",
                "datetime": 1785060420,
                "headline": "Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson?"
              },
              {
                "id": 141023596,
                "url": "https://finnhub.io/api/news?id=aa93f6b650dcda9f8826f3f7390c5a02e2548ec74e81335b1ebe7541cf3f7d9d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2187254257/image_2187254257.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Track this week’s market catalysts: Big Tech earnings, Fed rate decision, and core PCE inflation data—plus IPOs and key reports.",
                "category": "company",
                "datetime": 1785048021,
                "headline": "Wall Street Week Ahead"
              },
              {
                "id": 141020270,
                "url": "https://finnhub.io/api/news?id=7f9ee9e9891472b3ca8091ba21bc032ee3ef7180d7a8dcfe3d6ab7139cd24513",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Waiting until 70 to claim Social Security sounds simple until you calculate the eight years of income you need to survive without it. The dividend tier you choose to fill that gap could determine whether you arrive at 75 richer or quietly broke.",
                "category": "company",
                "datetime": 1785019617,
                "headline": "Claiming Social Security at 62 vs. Building a Dividend Bridge: Which Leaves You Richer at 75?"
              },
              {
                "id": 141017675,
                "url": "https://finnhub.io/api/news?id=3769ab2c0ea83f99ca7f597ad794b480628f778f45681fcadd0260d799ed512b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Genmab and AbbVie (ABBV) recently clarified that the U.S. portion of the Phase 3 EPCORE DLBCL-1 trial for epcoritamab did not meet its overall survival primary endpoint, raising fresh questions about the drug's long term commercial potential. See our latest analysis for AbbVie. Against this backdrop, AbbVie’s share price has had a strong run, with a 30-day share price return of 10.42% and a 90-day share price return of 30.52%. Its 1-year total shareholder return of 40.53% highlights momentum...",
                "category": "company",
                "datetime": 1784995784,
                "headline": "AbbVie (ABBV) Could Be 3% Undervalued Following Epcoritamab Trial Setback"
              },
              {
                "id": 141016843,
                "url": "https://finnhub.io/api/news?id=c8f64aaf8ca368f47b9c370c2b9d1f1ca3af5230aa897d88c88c075e19d32ed7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie has an attractive 2.7% yield, a solid pharmaceutical business, and is clearly focused on its dividend.",
                "category": "company",
                "datetime": 1784990100,
                "headline": "Why Wall Street Can't Get Enough of This Dividend King"
              },
              {
                "id": 141016864,
                "url": "https://finnhub.io/api/news?id=02a7054929fccd13b94135fcc42ef9eaf195056dd9ae3898a266d92a88bdf526",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Management's plain health care label has slipped out of the lead, and the business now on a separation clock is the one that finally started working.",
                "category": "company",
                "datetime": 1784989802,
                "headline": "Johnson & Johnson Is Becoming A Narrower Company Than You Bought"
              },
              {
                "id": 141016653,
                "url": "https://finnhub.io/api/news?id=2a9a468b4cda06411e0b3358a8f32ec8ca05e55f439a793c6c9ac9170bb0c9f1",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Wall Street Week Ahead: key earnings (AAPL, MSFT, META), Fed decision, GDP/PCE and IPOs—plus volatility, dividends and RSI screens. See more here.",
                "category": "company",
                "datetime": 1784977200,
                "headline": "Big Tech Earnings, Fed's Interest Rate Decision To Keep Next Week Busy"
              },
              {
                "id": 141012914,
                "url": "https://finnhub.io/api/news?id=9968dc5f0a39d2efae9a5c37aa5e7f90e134329e0f47c7edebe1e3236858774a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Just over a month since its initial public offering,  SpaceX  has delivered one of the weakest post-debut performances of any major U.S. listing since the end of the 2008-2009 financial crisis.  A Barron’s analysis found that the stock performed worse than 90% of other U.S. IPOs with market capitalizations of $1 billion or more since July, 2009.  Over the first 27 trading days,  SpaceX  was down 23% from its first day closing price of $161.",
                "category": "company",
                "datetime": 1784933040,
                "headline": "SpaceX Lands With a Thud"
              },
              {
                "id": 141007742,
                "url": "https://finnhub.io/api/news?id=1a4bd9a8e927b4e383f7109324d5417675ca77a48f556859be0ac2e47c6b2f72",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "JNJ's Innovative Medicine unit posts strong Q2 growth despite Stelara's patent loss. See what's fueling momentum into H2 2026.",
                "category": "company",
                "datetime": 1784903700,
                "headline": "J&J's Innovative Medicine Unit Proves Its Resilience in Q2"
              },
              {
                "id": 141006432,
                "url": "https://finnhub.io/api/news?id=8967641ac31cb8a4821e2a74c19e7270b7c5be7a5db018c5340e01a35ad83335",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1784901612,
                "headline": "AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release"
              },
              {
                "id": 141005874,
                "url": "https://finnhub.io/api/news?id=36c987ce04ee75dd31cd8b088c5db92bbebf79f032f9e455b0129572dcb17c89",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1627315719/image_1627315719.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "AbbVie offers a 2.7% forward dividend yield, outperforming peers by 68%, and maintains a 12-year streak of dividend growth. Find out why ABBV stock is a buy.",
                "category": "company",
                "datetime": 1784889960,
                "headline": "AbbVie: A Dividend Fortress At An Appealing Price Tag"
              },
              {
                "id": 141005736,
                "url": "https://finnhub.io/api/news?id=b0eb0f2c25c6209acafa711d38d4f6710c4762d68b8d1a160f1f2a1dac515ac4",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/24/Experts-Urge-Seniors-to-Stay-Vigilant.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie shares gained 1.4% to close at $256.92 on Thursday while Transocean shares rose 0.4% to settle at $5.32 during the session.",
                "category": "company",
                "datetime": 1784879595,
                "headline": "Netflix, AbbVie, Cerebras Systems And An Energy Stock On CNBC’s ‘Final Trades’"
              },
              {
                "id": 141005737,
                "url": "https://finnhub.io/api/news?id=09b0ee23712127e790437bd7239e1db83cc0d6bbe776a957098f94fa4e6d192b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/24/Closse-up-Shot-Of-White-Pills-On-Conveyo.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up to 200%.",
                "category": "company",
                "datetime": 1784874313,
                "headline": "Two Years to Build or Pay 200% — Which US Pharma Stocks Win?"
              },
              {
                "id": 140999570,
                "url": "https://finnhub.io/api/news?id=b63fe51b758812291dc983d692a3927bfad5b612f44e91146f4196fa56df4e45",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Media Release COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; July 23, 2026 Genmab and AbbVie clarify overall survival (OS) was the sole U.S. primary endpoint in the Phase 3 EPCORE® DLBCL-1 trial and was not met Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today provided clarification on the primary endpoints from the Phase 3 EPCORE® DLBCL-1 study evaluating monotherapy epcoritamab (DuoBody®-CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, compared with investigato",
                "category": "company",
                "datetime": 1784836800,
                "headline": "Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)"
              },
              {
                "id": 140997627,
                "url": "https://finnhub.io/api/news?id=161f9163fed82cb011751a2b6390549dda0724fd6e4069ed674acc35a1eb4b77",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "HDV quietly stacks a 3.1% income stream on top of equity gains that have left the S&P 500 in the dust this year, but the fund's concentrated sector bets carry a catch that most yield-seekers overlook.",
                "category": "company",
                "datetime": 1784835308,
                "headline": "HDV Delivers 3.1% Yield While Beating SPY Year to Date by 9 Points"
              },
              {
                "id": 140997478,
                "url": "https://finnhub.io/api/news?id=1de5038ef073af3ed66423bedc4fc046766610b7dfdc096d519b53d8bc890542",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "If you're looking for more frequent payouts, you can still enjoy the benefits of low fees and broad diversification, thanks to these top monthly dividend ETFs.",
                "category": "company",
                "datetime": 1784827913,
                "headline": "Best Monthly Dividend ETFs for Consistent Income"
              },
              {
                "id": 140994499,
                "url": "https://finnhub.io/api/news?id=d4fe36f615da1ffdb688b31fab610db1ed6153c0099afa303905b8f775240149",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "When quality goes on sale, it's time to back up the truck.",
                "category": "company",
                "datetime": 1784820900,
                "headline": "I'd Double a Position in These 3 Dividend Stocks Right Now Without Any Hesitation"
              },
              {
                "id": 139929915,
                "url": "https://finnhub.io/api/news?id=b79febb56b13c87a7cca143e78b5079c18f27f0b0e19568309d66e12a3a0ff7d",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "",
                "category": "company",
                "datetime": 1784811694,
                "headline": "From The ETF Professor: NFLX content deal helps SKYY, cloud computing ETF, hit high of the day. NFLX 6.6% of ETF's weight"
              },
              {
                "id": 140995076,
                "url": "https://finnhub.io/api/news?id=26f0a5f80d6fb8df924ff3c8ffaa28457c890f1186252a42f43bdbd5659ec44e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2217244120/image_2217244120.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "AbbVie stock rated Hold: strong Skyrizi/Rinvoq-led growth, but high debt, drug concentration, and valuation limit upside. Click to read more about ABBV.",
                "category": "company",
                "datetime": 1784808321,
                "headline": "AbbVie: Bright Future, But Already Priced In"
              },
              {
                "id": 140991887,
                "url": "https://finnhub.io/api/news?id=cfedbc9ae846e55911c677d2bfa09bf1416d379c66b235c3f64637c64f26f9b8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Drugmakers have announced 37 biotech acquisitions worth at least $1 billion this year, topping the previous annual record.",
                "category": "company",
                "datetime": 1784792789,
                "headline": "Missed AI, Memory Bull Run? Biotech May Be The Next Breakout Trade — But Retail Sentiment Has Never Been Lower"
              },
              {
                "id": 140984736,
                "url": "https://finnhub.io/api/news?id=2fbd4e839af7f7149a6b3e95694d3fbbb9d223f9d68fcf7f109c4a1b8a3d63c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "ABBV's Q2 oncology revenues may edge lower as Imbruvica weakness outweighs gains from Venclexta and newer cancer therapies.",
                "category": "company",
                "datetime": 1784738280,
                "headline": "Will AbbVie's Oncology Franchise Remain Under Pressure in Q2?"
              },
              {
                "id": 140981764,
                "url": "https://finnhub.io/api/news?id=fe4752d3fa507f1a71bb2fbc30af30104fbf8a525645ed5a3e73ad0ec80ed866",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "A pharmaceutical giant is on an incredible run fueled by blockbuster drugs, forcing investors to ask if the price of admission already accounts for the entire victory lap.",
                "category": "company",
                "datetime": 1784726247,
                "headline": "LLY Has Momentum. The Question Is The Price"
              },
              {
                "id": 140981615,
                "url": "https://finnhub.io/api/news?id=2f9c9575c82c8b7e73a95c3d96d13cfe3411bbcca5359a37a0a5341a439fca83",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2196897625/image_2196897625.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "The Voya Global Equity Dividend and Premium Opportunity Fund blends high current income with equity exposure. Read more on IGD CEF here.",
                "category": "company",
                "datetime": 1784713300,
                "headline": "IGD: Attractive Yield, But Discount Is Smaller Than Normal"
              },
              {
                "id": 140982340,
                "url": "https://finnhub.io/api/news?id=d158a4def2330ce18249f6a22c56b6a3750ac19776d255c2a1433a4b501ba3e2",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/22/Side-View-Of-Concentrated-Crypto-Trader-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Top analysts change outlook on top names. Baird, Canaccord Genuity, Needham, Stifel, Truist Securities raise price targets. See analyst ratings.",
                "category": "company",
                "datetime": 1784707615,
                "headline": "Synchrony Financial To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Wednesday"
              },
              {
                "id": 140983642,
                "url": "https://finnhub.io/api/news?id=08e597a010ad48e4330aadf75d7fb81348e2a9e85eb632b8dfdceadb94e5eecc",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Canaccord Genuity  analyst Gary Nachman   maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $273 to $282.",
                "category": "company",
                "datetime": 1784704564,
                "headline": "Canaccord Genuity Maintains Buy on AbbVie, Raises Price Target to $282"
              },
              {
                "id": 140978431,
                "url": "https://finnhub.io/api/news?id=d2e2a615989b328c659c405d43d35f56dc95988057516c9b2fe30f0818d6b855",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "In July 2026, Allergan Aesthetics, an AbbVie company, received European Commission approval for Boey (trenibotulinumtoxinE), a rapid-onset, short-duration botulinum neurotoxin serotype E for adults with psychologically impactful moderate to severe glabellar lines, following similar approval in Canada. As the first approved serotype E neurotoxin in Europe with effects beginning as early as eight hours and lasting about two to three weeks, Boey broadens AbbVie’s aesthetics portfolio with a...",
                "category": "company",
                "datetime": 1784682610,
                "headline": "How Investors May Respond To AbbVie (ABBV) Securing EU Approval For Short-Acting Boey Aesthetic Toxin"
              },
              {
                "id": 140977659,
                "url": "https://finnhub.io/api/news?id=2464e42d8202185bea7100aa306eb5acc9ecd1f3f128140db65a0e8ee321eee3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "It looks like a great buy-and-hold option.",
                "category": "company",
                "datetime": 1784674200,
                "headline": "3 Reasons to Buy AbbVie Stock Like There's No Tomorrow"
              },
              {
                "id": 140977660,
                "url": "https://finnhub.io/api/news?id=e8a9eb574172e4dce2c4492c356046352f248ecb11a07ea6eb3e2661011b858d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) closed at $256.18 in the latest trading session, marking a +1.11% move from the prior day.",
                "category": "company",
                "datetime": 1784670301,
                "headline": "AbbVie (ABBV) Beats Stock Market Upswing: What Investors Need to Know"
              },
              {
                "id": 140976349,
                "url": "https://finnhub.io/api/news?id=82d9525d03dbe9eedcd561c6aff3946e429bd9bd996312bd1f19747ca485afce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Management lifted its profit outlook, and investors have more than quadrupled that bet. The question now is what they're really paying for.",
                "category": "company",
                "datetime": 1784664282,
                "headline": "Eli Lilly Stock And The Price Of Confidence"
              },
              {
                "id": 140974897,
                "url": "https://finnhub.io/api/news?id=4527046ec46f67e07022ec64ce36d30476070db35309a16067f492a6176d2f66",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "This pharma giant is grabbing headlines, but its real value for your portfolio lies in how it moves on the market's worst days.",
                "category": "company",
                "datetime": 1784658705,
                "headline": "AbbVie Stock Zigs When The Market Zags"
              },
              {
                "id": 140976274,
                "url": "https://finnhub.io/api/news?id=368f308f78298308e28bab80965a366f9815383e3792f4e6d41714d0797503f7",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2214475209/image_2214475209.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Disc Medicine stock is slightly compelling, trading at ~$2.1 billion net of cash, with significant upside tied to bitopertin and DISC-0974 clinical milestones. Read the full analysis here.",
                "category": "company",
                "datetime": 1784656671,
                "headline": "Going Deeper On Disc Medicine"
              },
              {
                "id": 140973272,
                "url": "https://finnhub.io/api/news?id=0a1da48e1756e7d1552fedb7486e2efcbe6c7884d6f1dccfe14d398d732221b5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Strong biotech returns, major pharma acquisitions and new IPO filings are reshaping the 2026 U.S. listing market.",
                "category": "company",
                "datetime": 1784655971,
                "headline": "Biotech IPOs Surge 55% as AI Listings Lose Momentum"
              },
              {
                "id": 140970448,
                "url": "https://finnhub.io/api/news?id=4a0e1ac981bb5a7f38fee8acbaf68052de3d913022a498bdaffa2648573b9719",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "(Bloomberg) -- The biotechnology sector is stealing the US IPO market thunder from artificial intelligence-related listings, delivering standout returns as bankers line up a steady stream of summer debuts.Most Read from BloombergYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshot’s Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memory Than ComputeUS Strikes Iran in Escalating Cam",
                "category": "company",
                "datetime": 1784637325,
                "headline": "Biotech IPO Gains Crush AI Listings With Standout 55% Return"
              },
              {
                "id": 140969465,
                "url": "https://finnhub.io/api/news?id=1b34e6be29cc89ee95fc326d2194f47a17c3e7b5ff5a00519769067076ecd27d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Billionaire investors such as Peter Thiel and Christian Angermayer are believers in the benefits of using psychedelics derived from magic mushrooms...",
                "category": "company",
                "datetime": 1784606430,
                "headline": "Psychedelic drugs are going mainstream"
              },
              {
                "id": 140963403,
                "url": "https://finnhub.io/api/news?id=f4884d142c8fe4723c200af3df0c71c73b1c873e2c314a7447d92ad950c86ede",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The healthcare giant's pharma division is booming, but analysts on its latest call wanted to know if that's enough to cover for a sudden slowdown in MedTech.",
                "category": "company",
                "datetime": 1784573756,
                "headline": "Reading Between The Lines Of JNJ Stock's Latest Call"
              },
              {
                "id": 140960928,
                "url": "https://finnhub.io/api/news?id=2a801c948235c8d6a9e8789cf870b556394ce750ba69bb00b3f0b637a7d58ff2",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/20/Close-up-Of-A-Womans-Eyes.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "REGENXBIO announced positive long-term sura-vec trial data for wet AMD and diabetic retinopathy, alongside a $100 million offering.",
                "category": "company",
                "datetime": 1784544303,
                "headline": "Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments"
              },
              {
                "id": 140957651,
                "url": "https://finnhub.io/api/news?id=b48119d669b046cb291e67f2f812348161794131c0b00f6b915027443a57822d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as  Merck  Keytruda, the best-selling drug in the world.  Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies.  Bispecific antibodies are being tested by  Bristol Myers Squibb  (with its partner  BioNTech  ),  AstraZeneca  and the biotech firm  Summit Therapeutics  ADCs have already rung up big sales for Astra,  Pfizer Gilead Sciences  and  Roche Holding  but Merck has a strong contender in development.",
                "category": "company",
                "datetime": 1784527200,
                "headline": "What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment."
              },
              {
                "id": 140956242,
                "url": "https://finnhub.io/api/news?id=ed196c7764efdc62d80699b6fc0f1b2432a0f672ecc3f5133df8039022df7c9d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "There's no need to panic.",
                "category": "company",
                "datetime": 1784509500,
                "headline": "How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend?"
              },
              {
                "id": 140955778,
                "url": "https://finnhub.io/api/news?id=989fbbfabc0bbae37e46ab4bb57fb1e7723b8234cb8ccda6eb5366a42f05e17e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2285994413/image_2285994413.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Xencor (XNCR) stays a Strong Buy as XmAb819 and XmAb942 advance; key data due 2026–2027 and $542M cash extends runway—read the outlook now.",
                "category": "company",
                "datetime": 1784493770,
                "headline": "Xencor: Strong Buy, XmAb819 Presentation, And End Of 2026 XmAb942 Interim Data"
              },
              {
                "id": 140954711,
                "url": "https://finnhub.io/api/news?id=bd7f9275f6da066da0e062bbc8c0c2967aae456c9c00c3c32cd0ef0849b285c8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "They can help stabilize your portfolio in these otherwise volatile times.",
                "category": "company",
                "datetime": 1784492400,
                "headline": "My 2 Favorite Dividend Kings to Buy Right Now"
              },
              {
                "id": 140951671,
                "url": "https://finnhub.io/api/news?id=edcfdddd5026455494e57595a336d293ee28d8d9a3b6d45f94f6c9f02447669b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "All three pharma giants have left the S&P 500 in the dust, but surging returns and strong fundamentals tell very different stories about where each stock goes from here.",
                "category": "company",
                "datetime": 1784467858,
                "headline": "3 Biggest Pharma Giants: Buy, Sell or Hold?"
              },
              {
                "id": 140945969,
                "url": "https://finnhub.io/api/news?id=3e03a434a4559755dddff2e3cc1a900bc45590e4f46c2cf35cedac43e2f9ed50",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "REGENXBIO Inc. (Nasdaq: RGNX) today announced positive data from long-term follow-up studies of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in wet AMD using subretinal delivery and diabetic retinopathy (DR) using suprachoroidal delivery. These new data were presented at the American Society of Retina Specialists (ASRS) 44th Annual Meeting in Montreal, Canada.",
                "category": "company",
                "datetime": 1784400900,
                "headline": "REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting"
              },
              {
                "id": 140939161,
                "url": "https://finnhub.io/api/news?id=f57b9ce7b4402974f3ad4605a0ce95da73880c2e007cc7fb1d99cb560f207f71",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The drugmaker looks expensive today, but the real story is what you are actually paying for the earnings of tomorrow.",
                "category": "company",
                "datetime": 1784325063,
                "headline": "The Real Question Buried Inside Merck Stock's Premium Price"
              },
              {
                "id": 140936318,
                "url": "https://finnhub.io/api/news?id=2c4e4f3e4991a73c7a9ab8d42c56a63bc26445c0094e40e8ebc948ac02ee2028",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Allergan Aesthetics, an AbbVie company (NYSE:ABBV), received European Commission approval for Boey (trenibotulinumtoxinE). Boey is described as the first rapid onset, short duration neurotoxin for the treatment of frown lines available in Europe. This approval gives AbbVie a differentiated addition to its aesthetics portfolio in Europe, an area where the company already has an established presence. By targeting frown lines with a rapid onset profile and shorter treatment duration, Boey is...",
                "category": "company",
                "datetime": 1784315372,
                "headline": "AbbVie (ABBV) Wins EU Approval For Boey Frown Line Treatment In Europe"
              },
              {
                "id": 140934459,
                "url": "https://finnhub.io/api/news?id=a2ee62a66c63a946d94c3e6beb499c40b3125181a2923f5fa2fc732d6e9e4955",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "With 10-year Treasuries near 4.62%, VYM's $94.6 billion portfolio faces a real test from risk-free yields, and two familiar names inside the fund are quietly raising red flags about future income growth.",
                "category": "company",
                "datetime": 1784307459,
                "headline": "VYM’s $94.6 Billion Portfolio Beats Treasury Yields with Dividend Kings Leading the Way"
              },
              {
                "id": 140947353,
                "url": "https://finnhub.io/api/news?id=e61c23c6e5f6f1f9f9c4f2001f108f408862c47ea9e74ea2fe20cf32ff5112ca",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_4.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.69% on an annualized basis producing an average annual return of 14.83%. Currently, AbbVie has a market capitalization of $454.46 billion.",
                "category": "company",
                "datetime": 1784304950,
                "headline": "Here's How Much $1000 Invested In AbbVie 10 Years Ago Would Be Worth Today"
              },
              {
                "id": 140933581,
                "url": "https://finnhub.io/api/news?id=9a385d9550b1ee9b0a32e379b7afc16e0b87019409a9f9e52a697594be84c3b4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2206372673/image_2206372673.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "In this MoneyShow MoneyMasters Podcast episode, Jeffrey Hirsch, John McCamant, and Luke Lloyd discuss the forces shaping the stock market - and the best profit opportunities for H2 2026.",
                "category": "company",
                "datetime": 1784291400,
                "headline": "Where To Invest Now In AI, Biotech, Small Caps, And Gold"
              },
              {
                "id": 140931583,
                "url": "https://finnhub.io/api/news?id=25cece063d19d459865b9a99921860dfe97bea66365a006e1b97fa3d2d87b69e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the European Commission has approved Boey® (trenibotulinumtoxinE) in Europe, for the temporary improvement in the appearance of moderate to severe lines between the eyebrows seen at maximum frown (glabellar lines) in adult patients, when these have an important psychological impact.1",
                "category": "company",
                "datetime": 1784289600,
                "headline": "Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients"
              },
              {
                "id": 140935318,
                "url": "https://finnhub.io/api/news?id=2a20b2dc4b191277d497ed7580b8c9798ddae29e4fcd135aa0ded32541a4c1ed",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the European Commission has approved Boey® (trenibotulinumtoxinE) in Europe, for the temporary improvement in the appearance of moderate to severe lines",
                "category": "company",
                "datetime": 1784275467,
                "headline": "Allergan Aesthetics' Boey Receives European Commission Approval To Treat Moderate To Severe Lines Between The Eyebrows"
              },
              {
                "id": 140926081,
                "url": "https://finnhub.io/api/news?id=e64f76c09adafa515f4830316766b320a68890737e1611bda2f9562417d8f44b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Citi analysts laid out the appeal of biopharma stocks, with the NYSE Arca Pharmaceutical Index outrunning the S&P in the last month.",
                "category": "company",
                "datetime": 1784236020,
                "headline": "Why Healthcare Stocks Look Like a Haven in This Market"
              },
              {
                "id": 140924331,
                "url": "https://finnhub.io/api/news?id=2cccc71304a92dbf83c35d1711fa335b36545f9818f085bb547e2a190d5858bd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "ABBV's neuroscience business is expected to post solid Q2 growth, with key brands and Vyalev in focus ahead of earnings on July 31.",
                "category": "company",
                "datetime": 1784222460,
                "headline": "Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter?"
              },
              {
                "id": 140924212,
                "url": "https://finnhub.io/api/news?id=f1a83df4a460a5536afadd68c6d8b67158a8073b9c8875f11b1e6d8dfa1c018b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2268438699/image_2268438699.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Johnson & Johnson’s strong Q2 earnings, Spravato sales +41%, and raised 2026 EPS guidance. See why this analysis upgrades JNJ from Sell to Hold.",
                "category": "company",
                "datetime": 1784217215,
                "headline": "I Was Wrong About Johnson & Johnson: Upgrading To Hold (Rating Upgrade)"
              },
              {
                "id": 140920993,
                "url": "https://finnhub.io/api/news?id=53e72dfdc0a3fab7afbb6d59f65360596204973489784cf79e3fc6f96c90d9fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Abbott Laboratories (NYSE:ABT) reported second-quarter 2026 comparable sales growth of 4.8% and adjusted earnings per share of $1.31, with Chairman and Chief Executive Officer Robert Ford saying results marked an acceleration from the prior two quarters. The company reaffirmed its full-year compara",
                "category": "company",
                "datetime": 1784214288,
                "headline": "Abbott Laboratories Q2 Earnings Call Highlights"
              },
              {
                "id": 140920973,
                "url": "https://finnhub.io/api/news?id=383c8a910d0b53a4d210ac7d5f3ecafa0dbf367b7fec681eb1bd02c4862d419b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Abbott Laboratories posted slightly better-than-expected second-quarter earnings and raised its full-year profit outlook.",
                "category": "company",
                "datetime": 1784212620,
                "headline": "Why Abbott Stock Is Having Its Best Day in 24 Years"
              },
              {
                "id": 140923118,
                "url": "https://finnhub.io/api/news?id=849660181dbdce21c5283300d80d1ffbd4882504fe8ef32a9722935ced89a103",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Konskie--Poland---September-07--2025-Uni.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "UnitedHealth's (UNH) strong earnings and raised outlook lifted healthcare ETFs despite a sharp decline in Medicare Advantage membership.",
                "category": "company",
                "datetime": 1784208257,
                "headline": "UnitedHealth Rally Sparks Bullish Case for Healthcare ETFs Despite Medicare Advantage Losses"
              },
              {
                "id": 140919686,
                "url": "https://finnhub.io/api/news?id=73e8666060b1415c53da17946bd06f234dc80c8765b33ed82a66e02cf0745fc2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "While the market focuses on a single class of blockbuster drugs, a different story is unfolding inside the company. Lilly’s immunology, oncology, and neuroscience medicines are quietly compounding at a blistering pace. These other therapeutic areas collectively grew by 160% last quarter, a rate that suggests a much broader growth engine is taking shape.",
                "category": "company",
                "datetime": 1784207994,
                "headline": "What Could Push LLY Stock Higher From Here?"
              },
              {
                "id": 140919685,
                "url": "https://finnhub.io/api/news?id=8aaaa1ac492f93cd7e2c8a593e3ee9b65133645f1fcce9caf8568dc8cb52f96d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "While many investors focus on a slowdown in one business segment, they may be overlooking the remarkable growth occurring in another.",
                "category": "company",
                "datetime": 1784207994,
                "headline": "The Real Engine Behind Johnson & Johnson Stock's Next Climb"
              },
              {
                "id": 140919722,
                "url": "https://finnhub.io/api/news?id=bd3a772633121acf0452f10ab368b69a562e2c64a485ce99d79a2ec01db57828",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Abbott Laboratories posted slightly better-than-expected second-quarter earnings and raised its full-year profit outlook.",
                "category": "company",
                "datetime": 1784203500,
                "headline": "Why Abbott Earnings Are Sending the Stock Higher"
              },
              {
                "id": 140909591,
                "url": "https://finnhub.io/api/news?id=7f9bf71fadecdd9a92d2d7c8741a7205f9c570edb10edb3efdbbed51786a82c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Johnson & Johnson’s  second-quarter earnings were met with a shrug on Wall Street, but one of the drugmaker’s top executives insists the most powerful growth drivers are just starting to pick up speed.  J&J on Wednesday reported adjusted earnings of $2.90 a share, beating the $2.85 a share analysts had anticipated.  “I think the second quarter was just an affirmation of the first quarter,” Chief Financial Officer Joe Wolk said in an interview with Barron’s. “Our pharmaceutical unit continues to thrive, surpassing $16 billion in sales for the first time ever in the company’s history.”",
                "category": "company",
                "datetime": 1784128500,
                "headline": "Johnson & Johnson CFO Says This Drug Is Outperforming ‘Almost Any Launch’ in Recent Memory"
              },
              {
                "id": 140909595,
                "url": "https://finnhub.io/api/news?id=734ecd32e0b0bb076cabb9c846905c77fbf49fb3332c67befbe8f37a58387e50",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "ABBV stock rallies 9% YTD as Skyrizi and Rinvoq offset Humira declines, but can its pipeline, neuroscience growth and Apogee deal sustain long-term momentum?",
                "category": "company",
                "datetime": 1784126640,
                "headline": "Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise?"
              },
              {
                "id": 140909638,
                "url": "https://finnhub.io/api/news?id=7243ee1a85b76188f94e48cf78e769302cb5be15f4954fd7c2de0ef2546b5ae3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1784120412,
                "headline": "AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It"
              },
              {
                "id": 140907456,
                "url": "https://finnhub.io/api/news?id=ea90e871f4bebe869edd06014cb31d2873975e46465444a66adc34fbae80de5c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie and Baxter both flashed the same bullish technical signal this month, but one golden cross signals genuine momentum while the other masks a fundamentally broken business. Knowing which is which could protect your retirement income from a costly mistake.",
                "category": "company",
                "datetime": 1784115954,
                "headline": "AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap"
              },
              {
                "id": 140908262,
                "url": "https://finnhub.io/api/news?id=a3c02aed2f2d9e07701c9501ce2b08e8169b8f19ffb57cb4a98f015f765f168f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Johnson & Johnson (JNJ) delivered earnings and revenue surprises of +2.11% and +0.53%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1784115002,
                "headline": "Johnson & Johnson (JNJ) Q2 Earnings and Revenues Top Estimates"
              },
              {
                "id": 140914779,
                "url": "https://finnhub.io/api/news?id=4cf435faafeee26c2842f9966b9fe8dc9e2a04b13096d0e19fc58eb7f91a9ed6",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Citigroup  analyst Geoff Meacham   maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $230 to $260.",
                "category": "company",
                "datetime": 1784114317,
                "headline": "Citigroup Maintains Neutral on AbbVie, Raises Price Target to $260"
              },
              {
                "id": 140904224,
                "url": "https://finnhub.io/api/news?id=5579211571aba38bed935084064a09acd4f56873d9dc76a81dda9174b633e4f8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie stock has delivered a strong 151.6% return over the past five years, yet there is a clear split on valuation. A Discounted Cash Flow (DCF) intrinsic value estimate points to a large discount, while earnings based multiples suggest the shares trade on the rich side. AbbVie’s 151.6% gain over five years puts long term holders in a strong position. This can make fresh entry points and future returns more sensitive to what you pay today. Expectations around newer immunology and oncology...",
                "category": "company",
                "datetime": 1784067233,
                "headline": "AbbVie (ABBV) Stock Looks Fully Priced After A 152% Run"
              },
              {
                "id": 140902938,
                "url": "https://finnhub.io/api/news?id=8e300ea9fc804baa68fecb74e809b925e5842ab03cf3c0d5fd03354677cd567b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie, Enbridge, and Coca-Cola pay high dividends and are the types of stocks that investors can buy and forget about.",
                "category": "company",
                "datetime": 1784060400,
                "headline": "3 Rock-Solid Dividend Stocks to Buy and Hold for Decades"
              },
              {
                "id": 140901489,
                "url": "https://finnhub.io/api/news?id=cc7259599b4ee68c51c4b7851c608dd067bea716571dfea8637cbd3e4270e55c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "An obscure psychedelic is drawing intense interest from the pharmaceutical industry. WSJ explores why companies are betting hundreds of millions of dollars on the therapeutic potential of a toad poison.",
                "category": "company",
                "datetime": 1784055600,
                "headline": "The Race to Commercialize the World’s Most Powerful Psychedelic"
              },
              {
                "id": 140901439,
                "url": "https://finnhub.io/api/news?id=64cd56311f93e5171b803be30ef3da8f9f5b6d1c652a2a55be30635d893b79a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "In the world of big pharma, one company is both the star performer and the most expensive name on the marquee, forcing investors to ask if the price of admission is simply too high.",
                "category": "company",
                "datetime": 1784051674,
                "headline": "What Lilly's Peer-Beating Numbers Cost You"
              },
              {
                "id": 140902248,
                "url": "https://finnhub.io/api/news?id=40bf04d5730d9953faaebb0f7710b06678dc230e6d9574421efc3f181641f562",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2250479883/image_2250479883.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Syndax Pharma outlook: Revuforj first-mover edge, pipeline catalysts (Niktimvo), and profitability path amid misses. Click here to read more about SNDX.",
                "category": "company",
                "datetime": 1784047680,
                "headline": "A Fresh Look At Syndax Pharmaceuticals"
              },
              {
                "id": 140898040,
                "url": "https://finnhub.io/api/news?id=68a6715e91bd7ceaf0c6c6916c02776afd7f20a1e14b0e8a0d08338028065f8a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The company attributed the guidance cut to a larger-than-expected shift in payer mix and a greater financial impact from health insurance exchanges.",
                "category": "company",
                "datetime": 1784043119,
                "headline": "HCA Stock Plummets After Slashing 2026 Guidance – Marks Fifth Straight Day Of Losses"
              },
              {
                "id": 140898101,
                "url": "https://finnhub.io/api/news?id=c3bad6145b1e59b850a37af792ce7a0c27688aacb3cddf995c16d8d63961bf15",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "According to the average brokerage recommendation (ABR), one should invest in AbbVie (ABBV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
                "category": "company",
                "datetime": 1784035804,
                "headline": "Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?"
              },
              {
                "id": 140896885,
                "url": "https://finnhub.io/api/news?id=f830af9095f687cd4f1673a93a175fdc0b20a777f2c471ae61fb6a5d5fcdf8fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Conexeu Sciences is aiming CXU™ at the largest unclaimed frontier in injectable aesthetics: restoring body fullness at a scale today's fillers were never built to reach. The move builds on the company's completed 12-month P.R.O.O.F.™ preclinical studyHighlights An unclaimed opportunity. Large-volume body contouring, and restoration of the breasts, hips, and buttocks is a significant injectable aesthetics category yet to be claimed. History demonstrates the value of category creation. BOTOX® esta",
                "category": "company",
                "datetime": 1784032200,
                "headline": "The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It"
              },
              {
                "id": 140896886,
                "url": "https://finnhub.io/api/news?id=43cb7d991ac1a8b577b501fa9f758daac69a994fb433bb998448f424cd5d80b1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, is proud to announce SkinMedica's expanded commitment to regenerative science, advancing investments that will support innovation, research, clinical insight, and patient experience.",
                "category": "company",
                "datetime": 1784030700,
                "headline": "SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development"
              },
              {
                "id": 140899751,
                "url": "https://finnhub.io/api/news?id=d1aa5a730c62073f57143bd0a22d3a9540c6140220402a1e4e9ae24f822d7381",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.",
                "category": "company",
                "datetime": 1784030400,
                "headline": "Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill"
              },
              {
                "id": 140895235,
                "url": "https://finnhub.io/api/news?id=8d9777b0e7b101d7c72de663e31a949ba16e667fd31714d568fa328129eab30d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Drug pricing matters, but pipelines matter even more.",
                "category": "company",
                "datetime": 1784020800,
                "headline": "Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 223,
            "discarded_article_count": 190
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 15.9,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 0.4,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0.4,
            "vcp_reason": "站上MA50；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 5875630,
              "down_days": 5,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 5629580,
              "avg_vol_20": 5533570,
              "avg_vol_30": 5875630,
              "range_pct_10": 0.07451562576685979,
              "range_pct_20": 0.1047364602210168,
              "range_pct_30": 0.1047364602210168,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 0,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.9581236395075933,
              "dist_to_20d_high": 0.06224993457210165,
              "down_shrink_days": 2,
              "breakout_level_20d": 267.47,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.7114583174724021
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.687624484186888,
              "turnoverUsdM": 870.23582635563,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.ABBV",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 237.3378,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 1,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 5.4,
            "take_profit_price": 263.361,
            "target_multiplier": 1.6,
            "technical_strength": 1.38,
            "take_profit_percent": 5
          },
          "positionPoints": 1.6,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 5.375248968373776,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.ABBV",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 6.7411,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.69
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "弱勢",
      "score": 4,
      "value": -12.44
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.1691
    },
    "kdj": {
      "d": 34.67,
      "j": 67.61,
      "k": 45.65,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "超賣或超買風險",
      "score": 2,
      "value": 39.03
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 50122563,
      "recentSlope": -152643.7,
      "previousSlope": -209390
    },
    "rsi": 40,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 255.8246,
      "position": "SAR喺價上",
      "distancePct": 2,
      "previousTrend": "下降"
    },
    "ma50": 243.8126,
    "macd": {
      "macd": 0.6900344463409738,
      "trend": "中性偏多",
      "signal": 1.7730046246186544,
      "histogram": -1.0829701782776806
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 252.9125,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.64,
      "score": 2,
      "avgVolume": 5379273,
      "currentVolume": 3469563
    },
    "derived": {
      "ma20": 252.398,
      "ma50": 243.8126,
      "prevClose": 248.76,
      "avgVolume10": 5336196,
      "avgVolume20": 5379273,
      "changePercent": 0.83,
      "avgVolumeForScore": 5379273
    },
    "ma_cross": {
      "ma20": 252.398,
      "ma50": 243.8126,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 252.5765,
      "prevMa50": 243.1042,
      "spreadPct": 3.52,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 240.6393,
      "upper": 264.1567,
      "position": "中間"
    },
    "rsi_short": 69.35,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.64
    }
  }
}

{
  "close": 250.82,
  "volume": 3469563,
  "changePercent": 0.83
}